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ABSTRACT 
 
Background: Obesity is a disease characterized by excess adiposity which complicates 
metabolism, mobility, and multiple systems in the body. Over a third of Americans have a body 
mass index (BMI) greater than 30 kg/m2 and therefore, are considered obese. Excess adiposity 
may be prevented or reduced through behavioral, pharmacological and surgical methods. Bariatric 
surgery results in significant and sustained loss of body weight and body fat. Many bariatric 
surgeries have also been termed metabolic surgeries as they result in significant improvements of 
metabolic abnormalities associated with obesity including dyslipidemia and insulin resistance. It 
is estimated that 80% of individuals with Type 2 Diabetes Mellitus (T2DM) will experience 
resolution after bariatric surgeries such as Roux-en-Y gastric bypass and sleeve gastrectomy (SG).  
Although individuals with morbid obesity have a greater risk of T2DM, 25% remain insulin-
sensitive. To date, it is unclear why some develop insulin-sensitive obesity (Obsen) and others 
insulin-resistant obesity (Obres). A validated biomarker to distinguish these groups may aid in more 
targeted interventions and monitoring of at-risk populations. Fetuin-A (FetA) has shown promise 
as a potential marker of insulin resistance yet much about this hepatokine remains unknown.  
The overarching goal of this research is to understand whether FetA may be a novel marker of 
obesity and obesity-associated insulin resistance. Therefore, the objectives of this research were 
to 1) determine the role genetics play in circulating FetA and metabolic health, 2) investigate how 
circulating FetA responds to SG, a bariatric procedure known to markedly improve insulin 
sensitivity, and 3) compare FetA, adipocyte hypertrophy and weight loss trajectories between SG 
patients with Obsen and Obres. 
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Methods: To determine the genetic influence of FetA, 717 college applicants to the Autonomous 
University of San Luis Potosi, Mexico (18-25 years old) were genotyped for single nucleotide 
polymorphisms (rs4917 and rs2518136) in the gene that codes for FetA, alpha2-Heremans-Schmid 
Glycoprotein (AHSG). Circulating lipids, glucose, insulin and FetA were measured in plasma. To 
investigate the role of FetA in obesity and interventions aiming to improve insulin sensitivity, forty 
SG patients were recruited and evaluated longitudinally. Participants met with research staff at 
baseline (T0) (prior to hypocaloric, low-fat preoperative diet), on the morning of surgery (T1) and 
six weeks following surgery (T2). At each visit, fasting blood and three-day food logs were 
collected. Body composition was measured via direct segmental multi-frequency bioelectrical 
impedance analysis. Circulating FetA, insulin, blood lipids and glucose were measured at each 
visit. Omental adipose tissue was collected at the time of surgery. Formalin-fixed and paraffin-
embedded tissues were stained with hematoxylin and eosin, and adipocyte diameter was 
calculated. To compare individuals with Obres and Obsen, the cohort was divided into age- and 
BMI-matched groups based on homeostatic model assessment for insulin resistance (HOMA-IR) 
with consideration for diabetes diagnosis and use of anti-diabetic medications.  
Results: Individual genetic variation in AHSG SNPs rs4917 and rs2518136 explained 8% and 
10% of the variability in FetA, respectively. Lower triglyceride values were observed in CC-
rs4917 homozygotes than in T-allele carriers (p<0.05). In the SG cohort, FetA decreased 12% 
during the preoperative diet (p=0.007) and an additional 26% during the postoperative diet 
(p<0.0001). FetA was negatively associated with age (r= -0.52, p=0.004). Higher HOMA-IR at all 
time points was associated with lower FetA at T3 (HOMA-IR T0: p=0.002, T1: 0.003 and T2: 
0.001). Obsen and Obres groups did not differ in baseline BMI or percent body fat. Age-adjusted 
FetA tended to be higher in Obsen at T0 and T1 (p=0.09 and p=0.10, respectively). At T2, age-
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adjusted FetA was higher in the Obsen group than the Obres group (p=0.004). The Obres group had 
significantly more excess body weight loss (adjusted for baseline BMI and time) (p=0.012) and 
larger adipocytes than the Obsen group (p=0.0099). Adipocyte size was positively correlated with 
preoperative change in FetA (r=0.64, p=0.007) but not with reported changes in caloric intake, 
macronutrient intake, PBF loss or BMI loss. 
Conclusions: Variations in the AHSG gene influence circulating FetA and are associated with 
altered triglycerides. The influence of genetic variation was exaggerated in those who were 
overweight or obese. Individuals with obesity have higher FetA which is significantly reduced by 
calorie and fat restriction as well as SG. Immediate post-bariatric improvements of FetA have been 
correlated with rapid improvements in insulin sensitivity. However, decreased FetA may be 
partially explained by preoperative calorie restriction. Greater reduction in FetA during the 
preoperative diet was associated with smaller adipocyte size on the day of surgery. Smaller 
adipocytes have been shown to be more insulin-sensitive. Accordingly, individuals with Obsen had 
smaller omental adipocytes than those with Obres. In contrast to previous reports, those with Obsen 
tended to have higher circulating FetA at all time points, lost less weight, and had no appreciable 
improvements in HOMA-IR. This research demonstrates the potential of FetA as a marker for 
weight loss and insulin sensitivity improvements following lifestyle and bariatric interventions.  
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CHAPTER 1. LITERATURE REVIEW1 
1.1 Obesity 
According to the most recent data from the National Health and Nutrition Examination Survey, 
37.7% of American adults have obesity (1). Obesity is characterized by excess adiposity or fat 
accumulation in the body (2). Obesity categories are defined by the body mass index (BMI), which 
is calculated by dividing an individual’s body weight (in kilograms) by height (in meters) squared. 
Adults with a BMI greater than 30 kg/m2 are considered obese (3). This disease not only impacts 
adults but also one-third of children in the U.S. (4). Obesity in children is defined using the child’s 
height and weight compared to a standard growth chart of other age-matched children. These 
growth charts were created by the Centers for Disease Control and Prevention (CDC) and allow 
children to be assigned a percentile that reflects how they compare to a reference population that 
is matched for sex and age. Children who rank above the 85th percentile and below the 95th 
percentile are considered overweight. Children who are above the 95th percentile are considered 
obese (5).  
Obesity is a complex disease with multiple potential causes. The factors which increase the risk of 
obesity have been described by Harrison et al. (6). This team of transdisciplinary researchers 
developed the Six C’s model of obesity which suggests that the causes of obesity may be organized 
into six different spheres including the cell, child (or individual), clan, community, country and 
                                                          
1 Portions of this literature review were reprinted from Biochimie, 124, Robinson, KN. & Teran-Garcia, M., From 
Infancy to Aging: Biological and Behavioral Modifiers of Fetuin-A, No. 141-149, Copyright (2016), with 
permission from Elsevier and from Carle Selected Papers, 59/2, Robinson, KN., Rowitz, B. & Teran-Garcia, M.,  
Weight Loss Surgery: Mechanisms of Action and the Critical Role of Nutrition, No. 15-18., Copyright (2016), 
with permission from Carle Foundation Hospital.  
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culture (6). Examples of contributing factors include inadequate physical activity, poor diet 
quality, insufficient sleep, high parental BMI, aggressive food marketing, and traumatic life events 
(7–11). Poor diet quality may include inadequate intake of fruits, vegetables and fiber and 
excessive intake of sugar-sweetened beverages, dietary fat, and alcohol (12). Genetic variations 
can also predispose some individuals to weight gain (13). 
Early twin studies demonstrated a strong correlation between obesity and weight gain in 
monozygotic twins (r= -0.7, p=0.01) (14). Genetic factors have been estimated to explain 40-70% 
of the variation in weight (15,16). Genetic variation in proteins related to feeding regulation, taste 
preference, adipogenesis, insulin action and metabolism of lipids and energy have been 
investigated. The effects of these genetic variations depend on the location of the mutation and 
whether that mutation significantly modifies the protein structure thus leading to altered function. 
Although rare, it is possible for a single mutation to result in morbid obesity. So called, 
“monogenic” forms of obesity include mutations in leptin, leptin receptor, melanocortin receptor 
4 (MC4R) and Pro-opiomelanocortin (POMC) (17,18). These profoundly impact a pathway 
essential for weight balance and are characterized by early onset of obesity and severe 
hyperphagia. In the case of leptin deficiency, treatment with exogenous leptin leads to significant 
weight loss (17).  
While monogenic traits remain rare, polygenic obesity is thought to be more common. It is likely 
that obesity is promoted by the aggregate effect of multiple genes rather than a single mutation. 
Genome-wide association studies have identified >150 single nucleotide polymorphisms (SNPs) 
that are associated with BMI (19). From these findings, multiple genetic risk models have been 
created to predict obesity (20). Models have been constructed with a wide range of SNPs and have 
had conflicting results. Beyond obvious differences in the models, it is also possible that genes are 
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more tightly associated with weight balance over time rather than BMI at a single time point, which 
is currently the standard in genetic studies of obesity (18,21). Furthermore, GWAS of obesity-
associated mutations often assign BMI as the key outcome variable and fail to consider other more 
sensitive measures of adiposity. Thus, genetics are not currently used to predict obesity, but rather 
have offered important insight into the mechanisms behind obesity. For example, GWAS of BMI 
have identified genes with functions related to the brain and hunger cues to be significantly 
correlated with BMI. Conversely, GWAS of waist circumference have found genes associated with 
adipocyte biology to be significantly associated. This suggests that total body weight may be more 
so a result of perturbed satiety/hunger cues and that body composition (as measured by waist 
circumference) is the result of adipocyte differentiation, metabolism and remodeling.  
Obesity is a health concern due to its association with a higher risk for chronic disease, including 
type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) (22). Of individuals less than 
55 years old with BMI>30 kg/m2, men have a 10-fold higher risk of developing T2DM while 
women had a 2.5 fold higher risk of T2DM than lean counterparts (22). T2DM is a metabolic 
disorder characterized by high blood glucose (hyperglycemia) and high circulating insulin 
(hyperinsulinemia). When insulin, a hormone that facilitates glucose uptake, is chronically high in 
the blood, insulin resistance may result. When cells become resistant to insulin signaling, glucose 
is not taken up by the cell and therefore, remains in circulation causing a condition known as 
hyperglycemia and eventually T2DM. Uncontrolled T2DM can result in serious medical 
complications such as CVD, nephropathy, neuropathy, retinopathy, blindness, amputations, 
vascular dementia and premature death (23).  
Obese adults are more likely to experience risk factors for CVD such as hypercholesterolemia 
(high cholesterol), hypertriglyceridemia (high triglycerides) and hypertension (high blood 
4 
 
pressure) (24,25). Prevalence of coronary heart disease was two times higher in men with BMI>40 
kg/m2 and nearly three times higher in women with BMI>40 kg/m2 (22). The association between 
obesity and chronic diseases was initially discovered in adult cohorts and recently, similar trends 
have been reported in obese children.  
In regards to CVD, a study of obese children found that 70% had at least one risk factor for CVD 
and 39% had two or more risk factors for CVD (26). The Bogalusa Heart Study found that 
overweight children were 2.4 times more likely to have high levels of cholesterol, 3 times more 
likely to have high LDL, 3.4 times more likely to have low HDL, 7.1 times more likely to have 
high triglycerides and 4.5 times more likely to have high blood pressure than their normal weight 
peers (27). Additionally, T2DM was initially thought to be an adult onset disease, however, with 
the rising prevalence of childhood obesity, insulin resistance is being diagnosed earlier in life (28).  
Although obesity is associated with a higher risk of comorbidities, it should be noted that not all 
individuals with morbid obesity develop comorbidities. A quarter of individuals with BMI>35 
kg/m2 remain insulin-sensitive (29). Why this subset remains insulin-sensitive at higher categories 
of obesity, remains unclear. A review on the topic found several potential differences between 
individuals with insulin-resistant obesity (Obres) and insulin-sensitive obesity (Obsen). In 
comparison, those with Obsen consume lower amounts of total fat and saturated fat (30). In addition 
to these behavioral factors, those with Obsen also tend to have smaller adipocytes and greater lean 
body mass (31). However, longitudinal studies have suggested that Obsen and metabolically healthy 
obesity (MHO) are transitional periods. With aging, the prevalence of MHO decreases and 
comorbidities impact this population at a higher rate than their normal weight peers (32). 
Therefore, treatment options focused on reducing weight and improving body composition, would 
benefit those with Obres as well as those with Obsen. 
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Obesity Treatment 
Behavioral interventions including modifications to diet and physical activity are considered the 
first-line of obesity treatment. Dietary interventions for weight loss vary greatly and have evolved 
over the last few decades. This evolution is, in large part, driven by current research. Methods 
include reducing overall caloric intake, adjusting macronutrient distribution and limiting certain 
foods (sodas, sweets and dietary fats) (21). Data from the International Food Information Council 
Foundation suggest that one-quarter of Americans have made an effort to change their diet in the 
last year and 63% did so to lose weight (33). 
Unfortunately, dietary changes result in only modest weight loss. A meta-analysis of 27 self-
directed weight loss trials, revealed average weight loss of 2.7 kg at 6 months (34). One year of 
professional dietary counseling results in only a 1.9 kg/m2 reduction in BMI (35). Weight loss 
maintenance following these interventions has also been reviewed. Two to four years after lifestyle 
and dietary interventions weight loss was <5 kg (36). Likewise, a meta-analysis of 29 structured 
weight-loss programs found an average weight loss of 3kg five years after intervention (37). 
Fortunately, metabolic health may be significantly improved with just 5-10% weight loss (38,39).  
If behavioral modifications are unsuccessful at producing weight loss and an individual has a 
BMI>27 kg/m2, they may be eligible to receive pharmacological interventions. The list of 
approved weight-loss drugs is ever-changing. Most drugs are aimed at decreasing intake or 
increasing energy expenditure. When combined with a healthy diet, these medications result in 5-
10kg weight loss over a 1-2 year period (36). These medications may also help to control 
comorbidities. However, side effects may occur including elevated blood pressure, hypoglycemia 
and gastrointestinal-related adverse events (40,41). If pharmacological interventions continue to 
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provide only minimal results and an individual has a BMI>40 kg/m2 or >35 kg/m2 with 
comorbidities, they may be eligible for the third level of therapy: weight loss surgery also known 
as bariatric surgery. 
1.2 Weight Loss Surgery 
In 2013, 468,609 bariatric surgeries were performed worldwide, which is nearly 38% more than 
in 2011 (42). The most popular bariatric procedures were Roux-en-Y gastric bypass (RYGB, 
45%), sleeve gastrectomy (SG, 37%) and laparoscopic adjustable gastric banding (LAGB, 10%) 
(42). Of these operations, 154,276 were performed in the US and Canada; 35% RYGB, 43% SG 
and 10% LAGB. Although dietary and physical activity modifications are still commonly used 
methods for weight management, bariatric surgery results in greater weight loss and disease 
resolution especially in individuals with a BMI greater than 40 kg/m2. Weight loss 2-4 years 
following surgical intervention range from 25-75 kg (36). Nearly 80% of T2DM cases are resolved 
following surgery (43–45). Improvements are also seen with blood pressure, sleep apnea and 
hypercholesterolemia although resolution rates vary based on the type of procedure (43). A recent 
systematic review highlighted that health-related quality of life is consistently higher in bariatric 
patients 5-10 years postoperatively (46). Longitudinal data also suggests that 15 years following 
surgery, patients have a 30% lower mortality risk than individuals with obesity who did not 
undergo surgery (47). 
The surgery which results in the greatest weight loss and comorbidity resolution appears to be 
RYGB. This procedure involves creating a small gastric pouch which is anastomosed to the 
jejunum (distal to the ligament of Treitz). Thus following surgery, food bypasses the duodenum, a 
key site for the absorption of nutrients such as iron, calcium, folate and monosaccharides including  
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Figure 1.1 Common Bariatric Procedures Worldwide. 
           Roux-en-Y Gastric Bypass    Sleeve Gastrectomy           Adjustable Gastric Banding 
 
 
 
 
glucose (Fig. 1.1). RYGB patients lose an average of 61.6% of excess body weight at two-year 
follow-up (43). Outcomes are only slightly less effective in SG patients. During SG operations, the 
stomach is segmented vertically and nearly 80% of the stomach is removed. Therefore, SG patients 
retain their small intestine but no longer have the majority of the gastric fundus and body. Average 
excess body weight loss is 55.4% for SG patients (48). Gastric banding procedures are the least 
effective of these surgeries, however, offer the advantage of reversibility and fewer nutritional 
deficiencies (49). Gastric bands are FDA-approved, adjustable, tube-shaped devices that are placed 
around the proximal stomach which restricts the stomach size without altering the anatomy of the 
gastrointestinal (GI) tract. On average, band patients lose 47.5% of excess body weight (43). It is 
commonly assumed that weight loss and improvements in comorbidities are the result of dietary 
restriction; however, longitudinal studies have shown that RYGB and SG patients display unique 
metabolic changes that significantly differ from matched individuals undergoing a solely dietary 
intervention. Conversely, LAGB, a restrictive procedure, does not have metabolic effects which 
consistently differ from traditional weight loss interventions (50). 
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Mechanisms for Weight Loss and Disease Resolution following Weight Loss Surgery  
Traditionally, bariatric surgeries are categorized into three types based on the mechanism of action: 
1) malabsorptive; those resulting in alterations of the way the GI tract digests and absorbs food, 2) 
restrictive; those that reduce the volume of the stomach thus restricting the amount of food that 
can be consumed, or 3) a combination of both malabsorptive and restrictive. While this 
categorization may be helpful for teaching purposes, it grossly underappreciates the systemic 
changes that result following these surgeries. A description of the mechanisms of bariatric surgery 
(the BRAVE effects) has been published by Ashrafian et al. (51). The BRAVE effects include bile 
flow manipulation, reduced gastric size, anatomical changes to the GI tract resulting in altered 
nutrient flow and absorption, vagal signaling modification and enteric hormone alterations (51). 
While the BRAVE effects refer mainly to RYGB, this model also includes mechanisms of SG.  
Both RYGB and SG result in gastric restriction. Reduced gastric size may lead to weight loss by 
decreasing the size of meals. In response to having a smaller stomach pouch, patients may also 
alter the macronutrient composition of meals as some nutrients result in a greater perception of 
fullness. The duodenal bypass in RYGB has been considered a likely cause of diabetes resolution, 
however, does not explain the resolution rates observed in SG patients. Although SG does not 
result in anatomical changes to the small intestine, it may alter the speed of transport through the 
GI tract resulting in altered absorption. An additional consideration following these surgeries is 
the modification of the vagus nerve. The gastric branches of the vagus nerve, run along the lesser 
curvature of the stomach and are essential for cross-talk between the GI tract and the brain. It is 
more likely that the vagus nerve is significantly altered during RYGB rather than SG. This vagal 
nerve alteration may lead to changes in satiety signaling, GI motility, nutrient sensing and other 
signals in the gut-brain axis (52,53). 
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Enteric hormone changes may also explain the metabolic effects of bariatric surgery. One 
important hormone that is altered in response to bariatric surgery is ghrelin. Ghrelin promotes 
feelings of hunger and increases during calorie restriction, yet it decreases after bariatric 
procedures (54–56). Ghrelin appears to decrease more following SG than RYGB (57). One 
explanation for this phenomenon in SG is that ghrelin-producing cells are found in the portion of 
the stomach excised during surgery. Partial or complete gastrectomy dramatically reduces the 
stomach’s ability to produce ghrelin and may explain why some patients report no longer feeling 
hunger following surgery.  
Beyond the BRAVE effects, scientists are discovering that changes in gut microbiota may also be 
an important mechanism in bariatric surgery outcomes. A recent paper suggested that weight loss 
could be produced simply by transplanting the gut microbiota from rats that received RYGB to 
obese rats who had not received RYGB (58). Humans with obesity have a higher ratio of firmicutes 
to bacteroidetes than normal weight peers. Following surgery, the human gut microbiota shifts to 
reflect a unique profile, unlike individuals in either the obese or healthy BMI range (58,59). The 
reasons for these shifts and their influence on weight loss rate, weight loss maintenance and 
comorbidity resolution remain unclear. Because bariatric procedures offer unique benefits beyond 
weight loss, they may serve as an important model of study for the treatment of long-term obesity 
and obesity-associated diseases. 
Long-Term Efficacy of Bariatric Surgery  
According to the Swedish Obesity Study, the largest investigation of long-term bariatric surgery 
outcomes, maximum weight loss occurs 1-2 years after surgery (60). At this point, RYGB patients 
lose an average of 32% body weight and variable weight regain follows. On average, weight loss 
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at ten years post-RYGB decreases to 25%, and at 15 years, patients have lost 20 to 35% (average 
27%) of their baseline weight. From these data, it does not appear that weight regain surpasses 
baseline weight within the 15 years following surgery. Weight loss for LAGB patients reaches a 
maximum of 20% at 1-2 year follow-up but rises to 14% and 13% weight loss at 10- and 15-year 
follow-up, respectively (60). Still, at 15 years post-LAGB, weight regain does not exceed baseline. 
Long-term data for SG procedures is sparse. However, weight loss trends are similar to RYGB. 
Weight regain of 10 kg above weight loss nadir was seen in 19.2% of SG patients, however, these 
patients had still lost 20% of their excess body weight at five-year follow-up (61). Two systematic 
reviews have highlighted that the definition of weight recidivism is not yet standardized and that 
associated risk factors are still under investigation (62,63).  
Maximum weight loss has been positively associated with mandatory preoperative weight loss of 
5-10% (64). Preoperative hypocaloric diets are often prescribed in the two weeks before surgery. 
During the preoperative diet, the liver shrinks 14%, thus optimizing access to the gastroesophageal 
junction and reducing the risk of anastomotic leakage, abscesses and minor wound complications 
(65,66). Additionally, postoperative weight loss is negatively associated with preoperative BMI. 
Weight regain has been linked to preoperative binge eating disorder diagnosis and grazing 
although replication is needed (67). It remains unclear what factors influence the variability in 
postoperative weight loss and weight regain. However, a clear understanding is needed to improve 
patient care and procedure selection. As technology in the field of bariatric and metabolic surgery 
evolves, it is increasingly important that the nutritional status of these individuals is monitored and 
maintained. Moreover, early identification of patients at highest risk for postoperative nutritional 
and medical complications is critical.  
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Nutrient Deficiencies and Complications of Weight Loss Surgery 
Postoperative bariatric patients struggle to achieve adequate micronutrient intake because they 
consume a decreased amount of food and have GI alterations that modify the digestion and 
absorption of micronutrients. Extensive reviews have been published; however, common 
deficiencies include iron, vitamin B12, vitamin D and calcium (68). Following RYGB and SG, iron 
and B12 deficiencies occur in 32% and 11% of patients, respectively (69,70). Iron and B12 status is 
compromised due to inadequate dietary intake, malabsorption, and decreased acidity in the 
remaining stomach pouch (71). The stomach also contains parietal cells that release intrinsic factor, 
a necessary cofactor for vitamin B12 absorption. When the stomach is partially removed during 
bariatric procedures, secreted intrinsic factor is either significantly decreased or completely absent 
22 months following surgery (72). Thus, post-bariatric patients should aim to consume 150-200 
mg of elemental iron each day and B12 should be supplemented either orally (1000 µg per day) or 
intramuscularly (1000-3000 µg) every 6-12 months (73). 
Insufficient circulating vitamin D occurs in 23% of patients before surgery, 32% of patients 
following SG and 52% of patients following RYGB (74). Postoperative vitamin D deficiency may 
result if patients have inadequate intake, fat malabsorption or altered bile acid secretion (75). 
Because vitamin D is necessary to maintain blood calcium concentration, it has been suggested as 
a potential contributor to postoperative declines in bone mineral density and bone strength. 
However, rapid weight loss, in general, may also explain decreased bone health (76–78). For these 
reasons, bariatric specific guidelines suggest vitamin D and calcium citrate supplementation 
following surgery (73). Long-term monitoring is recommended to optimize patient outcomes and 
to ensure compliance with nutritional recommendations. However, at one year post-surgery, 
routine supplement use is only practiced by 26% of RYGB patients (79). Without supplementation 
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and monitoring, nutrient deficiencies persist and increase the likelihood of long-term 
complications such as decreased bone health, cognitive deficits and weight regain. 
This review of bariatric outcomes and complications highlights the variability inherent to weight 
loss surgery. Weight loss variability is not unique to bariatric surgery but occurs with all obesity 
treatments. The causes of variable weight loss are poorly understood making it difficult to predict 
which patients will experience the best outcomes. Multiple methods have been employed to predict 
outcomes including the collection of preoperative behavioral data and baseline genotyping. 
However, metabolomic studies may unveil novel biomarkers and provide a more complete picture 
of the biological changes underlying bariatric surgery outcomes. 
1.3 Fetuin-A: Structure and Function 
Fetuin-A, also known as alpha2-Heremans Schmid glycoprotein (AHSG), was first recognized 
because of its high concentration in fetal serum (80). Since being discovered, this hepatokine has 
been assigned multiple functions and circulating levels of Fetuin-A have been associated with 
numerous chronic diseases; most notably, CVD and T2DM (81–86) 
Fetuin-A (FetA) is secreted from the liver as a single chain precursor. The precursor is cleaved 
during proteolytic processing in the Golgi apparatus to form a heavy and a light chain consisting 
of 321 and 27 amino acids, respectively. A connecting peptide, which is 40 amino acids in length, 
is cleaved from the C-terminus of the heavy chain (87,88). The remaining chains are joined by six 
disulfide bonds. The final (mature) form of FetA has three domains. These domains contain 
important functional and structural features. The first domain contains a calcium-binding site. 
Domain 2 has three N-linked glycosylation sites and a phosphorylation site at Ser120. The final 
domain (Domain 3) contains two O-linked glycosylation sites as well as the second 
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phosphorylation site at Ser312. It is estimated that 20% of FetA is phosphorylated in at least one 
site (88). Phosphorylation appears to be essential for activation of FetA (89). 
Due to the calcium-binding site in Domain 1, FetA appears to have an important role in mineral 
transport and utilization. FetA can form complexes with calcium in circulation and, therefore, 
prevent soft tissue calcification (90). This function of FetA has been widely studied in dialysis 
patients, where low FetA levels in circulation have been linked to greater risk of cardiovascular 
events (91,92). At high levels, FetA reduces systemic calcification that contributes to the 
development of CVD (90,92,93). Alternatively, reduced FetA may also be a sign of inflammation. 
FetA has been identified as a negative acute phase protein because it is reduced in inflammatory 
conditions (94). FetA administration following LPS-infection is associated with greater survival 
risk (95). This is perhaps because FetA competes for binding at toll-like receptor 4 (TLR4) or 
dose-dependently increases phagocytosis (96). In an environment of chronic inflammation, FetA 
plays an important role in managing dying cells during apoptosis by enhancing phagocytosis (96). 
Although these findings support that low FetA is unfavorable, many other studies suggest that high 
circulating FetA is associated with obesity and T2DM.  
In obesity, FetA may also orchestrate macrophage migration and polarization in adipocytes by 
acting as a chemokine (97). In the pathophysiology of T2DM, FetA alters how muscle and adipose 
cells respond to insulin by inhibiting autophosphorylation of the insulin receptor (81). 
Additionally, cell culture and animal models have demonstrated that FetA plays an important role 
in the development of lipid-induced insulin resistance. Palmitate bound FetA activates TLR4; thus, 
signaling the release of proinflammatory cytokines, contributing to decreased insulin sensitivity 
(98). Therefore, it has been suggested that selective inhibition of FetA would lead to increased 
insulin sensitivity by allowing for autophosphorylation of the insulin receptor and decreased TLR4 
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activation. For this reason, FetA has been proposed as a target for developing therapies to 
ameliorate T2DM (83).  
Numerous researchers have used cohort studies to demonstrate the relationship between circulating 
FetA to obesity-associated diseases, mostly T2DM (84,99). Epidemiological evidence suggests 
that adults with higher FetA are at an increased risk for T2DM. The Nurses’ Health Study found 
that women in the highest quintile of FetA (≥0.57 mg/mL) had an approximately 1.8 fold higher 
risk of T2DM than women in the lowest quintile of FetA (≤0.40 mg/mL) (99). Similarly, the Health 
ABC study found that individuals with the highest tertile of FetA (>0.97 mg/mL) had a two-fold 
higher incident rate of T2DM than individuals with the lowest tertile of FetA (≤0.76 mg/mL) (84). 
While FetA has shown association with chronic disease, it has also been associated with other 
biological and behavioral factors. Biological processes impacting FetA include growth and aging. 
Current reports suggest that circulating FetA is highest during infancy (near 1mg/mL), declines 
into childhood (0.5-0.7 mg/mL) and varies in adults (100,101). Furthermore, developmental 
periods, such as menopause may influence FetA. In a cohort of older adults (median age: 71 yrs.), 
women taking estrogen had the highest FetA followed by women not taking estrogen. Men had 
the lowest FetA levels (86,102). Beyond aging, circulating FetA is also affected by genetics and 
responds to behavioral factors including dietary intake, physical activity and weight maintenance 
(Fig. 1.2). 
Variations in the Fetuin-A Gene 
The gene which codes for FetA, AHSG, is found on the twenty-seventh locus in the long arm of 
the third chromosome. Interesting, the 3q27 region has been identified as a T2DM and obesity 
susceptible region (103,104). Genetic variation may impact circulating FetA levels as well as risk 
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for T2DM and obesity-related phenotypes. Single nucleotide polymorphisms (SNPs) in the AHSG 
gene correlate with plasma FetA (105,106). In a cohort of 2,197 adults, the rs4917 polymorphism 
explained 21.2% of the variance in FetA with each C-allele increasing FetA by 0.035 mg/mL. To 
date, four SNPs have been found to be associated with circulating FetA (105). 
The correlation between AHSG SNPs and body composition is inconsistent (107–110). Multiple 
AHSG SNPs (rs2248690, rs2077119, rs4831, rs4917 and rs11540663) were genotyped in 364 
normal weight and obese women and no associations with BMI, percent body fat or waist 
circumferences were found (108). Another group genotyped rs4917 in 157 patients post-
myocardial infarction and a significant correlation with waist circumference and a borderline 
significant association with BMI was found (p=0.065). When analyzed under a dominant model, 
excluding individuals with T2DM, carriers of the minor T-allele of rs4917 (T/T or C/T) had 
significantly lower BMI and waist circumferences than C/C homozygotes (109). In another group 
of 504 normal weight and obese Swedish men, the G-allele of rs2593813 was associated with 
leanness. Three AHSG SNPs (rs2593813, rs4917 and rs4918) were used to construct haplotypes 
and variations of these haplotypes were more common in lean versus obese men. Specifically, the 
combination of a G-allele at rs2593813, a T-allele at rs4917 and a G-allele at rs4918 were 1.9 
times more common in men with a BMI less than 25 kg/m2 (110). Conversely, another research 
group used magnetic resonance imaging to assess regional body fat and was unable to show 
associations between body fat and genetic variations in the AHSG gene (111). Overall, it appears 
that SNPs in AHSG influence circulating FetA, but these SNPs are inconsistently correlated to 
BMI. Although some exonic AHSG SNPs result in nonsynonymous mutations, it is unclear 
whether the presence of these mutations alters the ability of FetA to bind to insulin receptor, TLR4, 
palmitate or other ligands (109). 
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Behavioral factors impacting circulating Fetuin-A 
Behavioral factors that impact FetA levels include physical activity, dietary intake and weight loss. 
Weight management strategies such as caloric restriction, aerobic exercise and weight loss 
surgeries have all been shown to reduce circulating FetA while overfeeding and obesity tend to 
increase FetA levels (112–115). A recent review paper has covered the topic of FetA and adult 
obesity in great detail and concludes that FetA is positively correlated with obesity and 
comorbidities and thus, may provide an interesting insight in the study of obesity-associated 
diseases (107). Circulating FetA is positively associated with obesity and weight gain and 
negatively associated with weight loss following behavioral intervention and bariatric surgery 
(112,116,117). In a five-year observational study, baseline FetA was positively associated with a 
gain of visceral adipose tissue in older adults. More specifically, each 0.42 mg/mL increase in 
FetA was associated with a 5% gain of visceral adipose tissue (118). In another study, researchers 
showed that a 34% decrease in BMI caused by Roux-en-Y gastric bypass (RYBP) led to a 19% 
decrease in FetA levels 16 months after surgery (112). In a different study of RYBP patients, FetA 
was 27% lower just three days after surgery when compared to FetA levels three days before 
surgery (116). It is unclear whether other bariatric surgeries cause similar decreases in FetA. 
Currently, only two studies have evaluated the impact of SG. One study included seven individuals 
and suggested that FetA decreased following SG although not significantly (116). The other 
included 22 SG patients and found that FetA was decreased by 13.8% (119). Therefore, the impact 
of surgery-induced weight loss on circulating FetA merits further investigation. It is also unclear 
whether the observed changes in FetA are due to bariatric surgery or due to dietary changes 
resulting from the surgery. 
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Figure 1.2 Individual Factors that Influence Circulating Fetuin-A.  
 
High-carbohydrate and high-fat diets promote the expression of FetA in hepatocytes and 
adipocytes and may result in higher circulating FetA levels in vivo (97). In one intervention study, 
plasma FetA was increased after overfeeding 40 healthy adults for 28-days (115). The composition 
of their diet was increased by 1100 kcals/d from baseline and modified to be composed of 45% 
energy from fat, 15% energy from protein and 40% energy from carbohydrates. This short report 
did not provide numerical values for baseline and post-overfeeding circulating FetA, so the 
magnitude of influence is not known. Furthermore, no descriptive information about the specific 
fatty acid content, the ratio of saturated fat to monounsaturated and polyunsaturated fatty acids or 
other nutrition details were reported. As stated previously, FetA preferentially binds the saturated 
fatty acid, palmitate, and signals the TLR4 inflammatory cascade (97,98). While free fatty acids 
at high concentrations were positively correlated with circulating FetA in one study, there is no 
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conclusive evidence on whether the type of dietary fat increased during overfeeding alters the 
transcription of FetA or the ability of FetA to signal TLR4 (120).  
The impact of calorie restriction on FetA levels appears to conflict in two studies of different 
populations. The first study included overweight women with T2DM. These women were 
instructed by a dietitian on how to reduce their energy intake by 30% (an average of -586 kcal per 
day). For 12 weeks, calories were restricted and the result was a 7% decrease in FetA when 
compared to a control group (0.23 mg/mL and 0.25 mg/mL, respectively, p=0.04) (113). 
Conversely, the second study included individuals who were considered to have restricted calorie 
intake due to intentional self-restriction, excessive exercise and low body weight. This type of 
calorie restriction – short or long-term – had no impact on FetA (121). This report also found no 
differences in circulating FetA in short-term calorie restriction (72-hour fasting) in men and 
women with a BMI less than 25 kg/m2 (121). Therefore, the impact of calorie restriction on 
circulating FetA may depend on baseline body composition with overweight individuals showing 
a larger response to calorie restriction than normal or underweight individuals. 
Of note, the correlation between FetA and obesity is understudied in children. One existing study 
found that FetA was not significantly different between normal weight and obese children. 
However, obese children with non-alcoholic fatty liver disease (NAFLD) had significantly higher 
circulating FetA (0.35±0.07 mg/mL) than obese children without NAFLD (0.29±0.06 mg/mL) 
(122). This study may suggest that metabolically unhealthy obesity but not metabolically healthy 
obesity is positively correlated to FetA. 
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1.4 Conclusion 
In summary, obesity is a complex disease that increases the risk for numerous, life-threatening 
chronic conditions. Bariatric surgery leads to long-term weight loss as well as improvements in 
comorbidities. It is not entirely clear why comorbidities such as T2DM resolve following bariatric 
procedures. As our understanding of the mechanisms behind these diseases evolves, new 
biomarkers such as FetA may provide novel insight into predicting disease risk, assessing disease 
progression as well as provide new targets for treatment. FetA is a multifunctional protein that 
inhibits ectopic calcification and insulin signaling via tyrosine kinase. FetA also promotes 
inflammation through TLR4. Increased levels of FetA have been linked to greater risk of CVD 
and incident T2DM. Therefore, it has been proposed as a biomarker for these diseases. To fully 
understand the clinical utility of FetA as a biomarker for disease, consideration must be given to 
the biological and behavioral factors influencing FetA. Biological factors include genetics and 
aging among others.  
Behavioral factors that impact FetA levels include physical activity, weight loss and dietary intake. 
In general, physical activity and weight loss (either by behavioral modification or weight loss 
surgery) decrease FetA (114,123). Although research concerning the diet’s impact on FetA is 
sparse, it appears that excess calorie intake increases FetA while low-calorie diets reduce FetA. 
Therefore, if FetA does prove to be an informative clinical marker of CVD or T2DM, it may also 
be possible to manage FetA through physical activity, weight management and diet in addition to 
pharmacological means.  
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CHAPTER 2. OBJECTIVES AND SPECIFIC AIMS 
 
2.1 Rationale and Significance 
Obesity is a life-changing disease, which is associated with higher risk of comorbidities including 
T2DM (25). Uncontrolled T2DM can lead to neuropathy, nephropathy and retinopathy, which 
cause physical, emotional and financial burden (124). In 2012, the cost attributed to diagnosed 
cases of T2DM was $245 billion in the U.S. alone (125). Effective treatments for obesity and 
T2DM would significantly improve the quality of life for millions of Americans.  
While weight loss has been shown to improve diabetes-associated markers, behavioral 
interventions are only marginally effective at producing sustained weight loss. Pharmacological 
drugs have been modestly successful, yet concerns about side effects and long-term safety exist 
(126,127). To date, the most successful treatment for obesity is bariatric surgery, which results in 
significant weight loss as well as resolution of diabetes in 80% of patients (128,129). Due to these 
dramatic improvements in insulin sensitivity, bariatric surgery has served as an interesting model 
for the study of diabetes mechanisms. By studying disease resolution, researchers may achieve a 
different view of disease progression and discover new targets for intervention.  
FetA is a novel protein that links obesity and T2DM. By studying FetA, we gain important insights 
into whether FetA has the potential to serve as a biomarker for these diseases. This research 
provides is a greater understanding of how FetA relates to obesity while considering multiple 
biological and behavioral factors such as genetics and dietary intake. By determining how FetA 
responds to bariatric surgery, we may be able to better understand what role is has in the resolution 
of T2DM. Circulating FetA has been shown to respond to changes in BMI, however, our study 
will gather more specific measures of body composition including percent fat mass and lean body 
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mass. Furthermore, by studying AHSG SNPs in multiple populations, we aim to elucidate whether 
AHSG polymorphisms relate to differences in T2DM prevalence between ethnic groups. 
2.2 Scope of Research 
Novel biomarkers have the potential to inform clinical practice and improve patients’ lives. 
Biomarkers may be used as diagnostic tools or therapeutic targets. In this dissertation, we aim to 
evaluate the potential of FetA as an indicator of insulin resistance in obesity. FetA is just one of 
many proteins in the body whose function is not fully understood. This cumulative body of work 
will contribute further clarity on the response of FetA to surgically-induced weight loss and 
diabetes resolution.  
Although FetA has been described in many disease states, there are substantial gaps in the 
literature. Questions that remain include: how do polymorphisms in AHSG influence circulating 
FetA in ethnic groups with elevated risk for T2DM? If FetA decreases with weight loss, are 
changes in adiposity or dietary intake more influential? Could changes in FetA partially explain 
increased insulin sensitivity following bariatric surgery? Overall, this research will add to the 
understanding of FetA in response to weight loss and describe the influence of AHSG 
polymorphisms. 
2.3 Objectives and Specific Aims 
The overarching goal of this research proposal is to understand whether FetA may be a novel 
marker of obesity and obesity-associated insulin resistance and to elucidate the association 
between obesity, circulating FetA and AHSG polymorphisms. We aimed to understand FetA’s 
role in obesity-associated chronic diseases and to describe the impact of AHSG SNPs on 
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circulating FetA and blood markers of metabolic health. We explored the impact of surgically-
induced weight loss on FetA and determined whether FetA correlates with increasing insulin 
sensitivity following weight loss surgery. Finally, we sought to determine whether circulating FetA 
and FetA trajectories differed in bariatric patients with insulin-sensitive and insulin-resistant 
obesity.  
Hypothesis 1: Single nucleotide polymorphisms (SNPs) in AHSG will alter circulating FetA and 
markers of metabolic disease in young Mexican adults. 
Chapter 3 highlights metabolic differences in individuals carrying different genetic 
variants of AHSG. Specifically, AHSG genotype was associated with circulating FetA and 
triglycerides but not with BMI or waist circumference in a college-aged Mexican 
population. Variation in these SNPs explained 8-10% of the variability in FetA.  
Hypothesis 2: Significant reductions in FetA following SG begin prior to surgery during the 
preoperative diet.  
Chapter 4 presents evidence of a significant preoperative decline in FetA that compliments 
the postoperative decline in FetA reported in previous studies. Total change in FetA was 
associated with percent weight loss. Interestingly, HOMA-IR at all time points was 
associated with postoperative FetA. Considering the significant change in FetA during this 
time period and the association with weight change and insulin resistance, we sought to 
determine whether individuals with insulin-resistant obesity responded differently to 
bariatric surgery than those with insulin-sensitive obesity.  
Hypothesis 3: Individuals with insulin-resistant obesity will have significantly different weight 
loss and FetA change over the course of SG than individuals with insulin-sensitive obesity. 
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Chapter 5 summarizes the influence of FetA change over adipocyte hypertrophy and 
insulin status. Contrary to previous findings, FetA tended to be higher in individuals with 
Obsen than those with Obres. Although baseline BMI and percent body fat did not differ, the 
Obres group had significantly more excess body weight loss and larger omental adipocytes. 
Furthermore, greater preoperative reduction in FetA was associated with smaller 
adipocytes on the day of surgery. 
Chapter 6 reviews the contributions of this research and postulates future areas of interest in the 
study of FetA, bariatric surgery and obesity. Specifically, a better understanding of how FetA 
influences adipocyte size and function is needed. Continued pursuits into the mechanisms behind 
bariatric surgery will shed light on the etiology and resolution of obesity-associated diseases. Also, 
more research is needed concerning long-term outcomes and the potential use of bariatric 
procedures in specific populations including adolescents and adults with class I obesity.  
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CHAPTER 3. Α2-HEREMANS-SCHMID GLYCOPROTEIN (AHSG) 
POLYMORPHISMS ARE ASSOCIATED WITH CIRCULATING FETUIN-
A AND TRIGLYCERIDES IN YOUNG MEXICAN ADULTS 
 
Abstract  
Background: Circulating Fetuin-A (FetA) inhibits insulin receptor signaling and activates the toll-
like-4 receptor proinflammatory cascade, thus, may contribute to Metabolic Syndrome (MetS) 
development. The FetA protein is coded by the Αlpha2-Heremans-Schmid Glycoprotein (AHSG) 
gene. Polymorphisms in AHSG could influence MetS progression in higher risk ethnic groups. We 
aim to identify if AHSG individual variation relates to biomarkers of metabolic disease and obesity 
in young Mexican Adults.  
Methods: Participants were college applicants to the Autonomous University of San Luis Potosi, 
Mexico (18-25 years, n=717). Blood was collected for analysis of biomarkers, circulating FetA 
and genotyping. A sample of this cohort was analyzed five years after baseline visit to assess 
longitudinal changes (n=74). Two single nucleotide polymorphisms (SNPs) in AHSG were 
genotyped (rs2518136 and rs4917).  
Results: Lower triglyceride values were observed in CC-rs4917 homozygotes than T-allele 
carriers (p<0.05). There was no association with AHSG SNPs and body mass index or waist 
circumference. Both SNPs were significantly associated with circulating FetA. Variation in rs4917 
and rs2518136 explained 8% and 10% of the variability in FetA, respectively. 
Conclusions: Circulating FetA was influenced by AHSG polymorphisms. Rs4917 T-allele carriers 
had higher triglycerides and this relationship was exaggerated in overweight and obese individuals. 
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3.1 Introduction  
Obesity is associated with a higher risk for multiple comorbidities including Type 2 Diabetes 
Mellitus (T2DM), dyslipidemia and Metabolic Syndrome (MetS) (22). Fetuin-A (FetA) is both a 
hepatokine and an adipokine which is increased in patients with these conditions. FetA inhibits 
insulin receptor tyrosine kinase, thus reduces insulin sensitivity via decreased translocation of 
glucose transporter type 4 (130,131). More recently, FetA has also been shown to bind saturated 
fatty acids and stimulate inflammatory cytokine release via toll-like receptor 4 (98). Accordingly, 
circulating FetA has been positively associated with increased risk for T2DM (84). Circulating 
FetA levels are higher in individuals with T2DM and are positively correlated with fasting blood 
glucose levels (106). Additional factors associated with elevated FetA such as physical inactivity 
and dietary intake have been reviewed elsewhere (132).  
The gene which codes for FetA, Αlpha2-Heremans-Schmid Glycoprotein (AHSG), is located in 
the diabetes-susceptible gene locus 3q27 (103,104). A few SNPs in AHSG (i.e. rs2077119 and 
rs2518136) have been associated with greater risk for T2DM (109,133). Circulating FetA has also 
been correlated to markers of cardiovascular disease and dyslipidemia (133,134). In the EPIC-
Potsdam Study, FetA levels were positively associated with total cholesterol (105). Dahlman et 
al., also found that three AHSG SNPs were correlated to cholesterol (rs2248690, rs2077119 and 
rs4917) (108). Conversely, other studies have reported no difference in cholesterol concentration 
between rs4917 genotypes (109,110).  
It is unclear at this time what role AHSG SNPs have on body composition (108–110). Knock-out 
mice for AHSG are resistant to diet-induced obesity (135). In human studies, AHSG SNPs are 
inconsistently correlated with measures of obesity. The functional AHSG SNP, rs4917, is the most 
26 
 
commonly studied. Two studies found evidence to support an association between rs4917 and 
obesity while two others found no association. In 2005, Lavebratt and collaborators investigated 
the association between AHSG SNPs and obesity. Three SNPs (rs2593813, rs4917 and rs4918) 
were genotyped in 504 normal weight and obese Swedish men. Lean men were 1.9 times more 
likely to have a G-allele at rs2593813, a T-allele at rs4917 and a G-allele at rs4918 compared to 
overweight or obese men (110). In a previous study of 364 Scandinavian women, six AHSG SNPs 
(including rs4917) were genotyped and no association was found with body mass index (BMI), 
waist circumference or percent body fat calculated from DEXA measurements (108). Mussig et 
al. measured body fat distribution using magnetic resonance imaging and found that location of 
body fat was also not correlated with genetic variations in rs4917 (111). Therefore, it appeared 
that AHSG SNP rs4917 was not likely correlated to body composition. Recent evidence from 
Hungarian researchers, however, demonstrated that the T-allele in rs4917 was in fact, associated 
with leanness, just as Lavebratt et al. had suggested a decade earlier (109). The reason for the 
reported inconsistencies remains unknown although population stratification and differences in 
allele frequencies may play a role.  
It is not clear how these polymorphisms are involved in the pathophysiology of obesity-
comorbidities. One plausible explanation is the ability of AHSG polymorphisms to modify 
circulating levels of FetA. Three studies have demonstrated that AHSG SNPs influence the level 
of FetA in circulation (105,106,136). In a European population, each C-allele at rs4917 increased 
FetA by 0.035 mg/mL (105). Polymorphisms at this site explained around 21% of the variance in 
FetA. The researchers went on to show that three other SNPs, including rs2070633 and rs2070635, 
were associated with circulating FetA (105). This finding was re-evaluated by Jensen and 
collaborators. In both Caucasian and African American adults, AHSG rs4917 T-allele carriers had 
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13% and 11% lower circulating FetA, respectively (106). The most recent data to support a 
connection between AHSG polymorphisms and FetA levels comes from the EPIC Study. Among 
483 participants, rs4917 C-allele carriers exhibited 16-28% higher plasma FetA (136). Overall, the 
results of these three studies consistently suggest a role for genetics in the determination of FetA 
levels. However, the reported difference between ethnicities warrants further investigation.  
The associations of FetA with T2DM, dyslipidemia and MetS have been demonstrated in mostly 
Caucasian cohorts. The SNPs identified in genome-wide association studies (GWAS) of 
Caucasians are not always consistent with SNPs identified in GWAS of other ethnicities (137). To 
date, the influence of AHSG polymorphisms in other ethnic groups at higher risk for obesity is 
understudied. Compared to Caucasian groups, Hispanics have higher rates of T2DM and other 
obesity comorbidities. The Mexican population is one of the groups at highest risk of all Hispanic 
subgroups. Furthermore, Hispanic and Caucasian populations have different frequencies of minor 
alleles at AHSG, making this a gene of interest in the study of health disparities.  
In this report, we aim to identify whether individual genetic variations in AHSG relate to 
biomarkers of metabolic disease as well as circulating FetA in a cohort of young Mexican adults. 
We will also describe the impact of these markers on longitudinal weight and metabolic changes 
in a subset of individuals that were followed up to five years after initial recruitment. 
3.2 Methods  
The UP-AMIGOS cohort (Universities of San Luis Potosí and Illinois: A Multidisciplinary 
Investigation on Genetics, Obesity, and Social-environment) included young adult applicants to 
the Autonomous Universities of San Luis Potosí (USLP) (n=717). The study protocol was 
approved by the Institutional Review Boards of the University of Illinois at Urbana-Champaign 
28 
 
and USLP. Height to the nearest centimeter, weight to the nearest 0.1 kg and waist circumference 
(WC) to the nearest 0.1 cm were measured by trained UP-AMIGOS staff. Fasting blood was 
collected for the analysis of biomarkers and genotyping. Fasting glucose was measured using 
reagents from BioSystems (Barcelona, Spain) and the Alcyon 300 Auto Analyzer (Abbott Park, 
IL, US). A colorimetric enzymatic reaction was used to assess triglyceride (TG) levels and high-
density lipoprotein (HDL) was measured according to the cholesterol oxidase method. 
Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) was calculated using 
Matthews’ equation (fasting insulin (µU/ml) x fasting blood glucose (mmol/l) divided by 22.5) 
(138). The UP-AMIGOS cohort also includes a longitudinal arm, which contains 74 individuals 
from the original cohort that participated in a follow-up appointment five years after admission to 
college. Plasma samples were collected from these participants and FetA concentrations were 
determined by enzyme-linked immunosorbent assays provided by BioVendor™ (Asheville, NC). 
Genomic DNA was extracted from whole blood using a commercially available kit (Gentra 
Puregene Blood Kit, Qiagen, CA) and stored at -20°C until analysis.  
After consideration of minor allele frequency (MAF, minimum of 10%) and location of possible 
SNPs in the AHSG gene, two SNPs were selected (rs2518136 and rs4917). Rs2518136 
(IVS6+98C>T) is located in the sixth intron. According to the 1,000 Genomes Project, the C-allele 
is the minor allele in the majority of populations (Global MAF: 48%). Rs4917 is located in the 
sixth exon of the AHSG gene and the T-allele is the minor allele (Global MAF: 26%). The presence 
of a C-allele at this site results in a nonsynonymous substitution (Thr230Met). Both of the selected 
SNPs serve as tag SNPs meaning they are in high linkage disequilibrium with other SNPs of 
interest and may be used to identify genetic variation at other sites within the AHSG locus. 
Rs2518136 is a tag SNP for rs2070633 and rs2070635. Genetic variation at these locations, 
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specifically rs2070633-TT and rs2070635-AA have been associated with lower FetA 
concentrations (105). Rs4917 is a tag SNP for rs2593813 and rs1900618. The rs2593813-GG 
genotype was two times more common in lean individuals than in overweight or obese 
counterparts (110). Therefore, our rationale for the selection of these SNPs (rs2518136 and rs4917) 
is based on previous literature, minor allele frequencies greater than 10%, tag SNP potential and 
the need to better understand the genetic and metabolic differences between ethnic groups.  
Samples of the UP-AMIGOS cohort (n=747) were genotyped at the Functional Genomic Unit of 
the W.M. Keck Center at the University of Illinois using the Fluidigm® SNP genotyping platform. 
Genotypes were called using the Fluidigm® Genotyping Analysis Software version 4.1.2 (San 
Francisco, CA) with a minimum of 95% confidence. Samples that failed genotyping for either 
marker were excluded (n=30), leaving a final sample size of 717 participants. Comparative MAFs 
are listed in Table 3.1.  
Associations between AHSG SNPs, circulating FetA, obesity parameters and comorbidity 
measures were analyzed using SAS 9.3 (Cary, NC). Generalized linear models and chi-square tests 
were used to identify associations within genotypic, recessive and dominant models (SAS 9.3). 
Skewed variables were log-transformed for analysis and back-transformed for interpretation. 
Models were adjusted for age, sex and BMI, when appropriate.  
3.3 Results  
A total of 717 participants (44% male) were included in this analysis. Descriptive characteristics 
are included in Table 3.2. At baseline, the average age of the participants was 18.5±1.3 years and 
the average BMI was 23.8±4.5 kg/m2. Of the population, 7.8% were underweight, 59.3% had a 
BMI within the normal range and 32.9% were categorized as overweight or obese. Both SNPs 
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were in Hardy-Weinberg Equilibrium according to chi-square analysis (p>0.05). Our cross-
sectional analysis of the entire cohort showed that neither SNP was associated with BMI or WC 
(Table 3.3).  
The longitudinal cohort included 75 returning participants with an average age of 23.4±1.9 (37% 
male) at follow-up. BMI was positively correlated with fasting plasma FetA (r2=0.12, p=0.03) 
when adjusted for age. Circulating FetA was not associated with glucose, TG, HDL, LDL or WC. 
Average weight gain over five years was 8.5±10.9 percent of body weight. The prevalence of 
overweight and obesity climbed by 9% (from 32% at baseline to 41% at follow-up). Changes in 
weight and BMI over this time period were not associated with age, sex, baseline BMI or baseline 
WC. However, changes in WC were associated with sex (r2= 0.08, p=0.01) and with baseline WC 
(r2=0.05, p=0.05). At follow-up, WC decreased by 2.9±7.8 cm in females and increased by 2.9±9.4 
in males. Neither AHSG SNP was associated with changes in weight parameters in the longitudinal 
cohort (Table 3.4). 
Circulating levels of FetA were associated with AHSG rs4917 and rs2518136 
The presence of the T-allele at rs4917 was associated with 8% lower circulating FetA (Table 3.5). 
Each T-allele decreased circulating FetA by 30.0 µg/mL (p=0.03). The T-allele at rs2518136 was 
also associated with lower FetA and each T-allele resulted in an average FetA decrease of 32.5 
µg/mL (p=0.04).  
Circulating triglycerides were associated with AHSG rs4917 
Rs4917-CC homozygotes had lower TG values than T-allele carriers (106.5±48.0 vs. 121.1±58.3 
mg/dL, p=0.02) (Fig. 3.1). When split by BMI category, it appears that obesity amplifies the 
genotypic influence of this AHSG SNP (Fig. 3.2). Homozygotes for the T-allele that were 
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overweight or obese had higher TG than CC-homozygotes that were overweight or obese 
(122.5±61.5 vs. 149.8±56.6 mg/dL). Regardless of the AHSG genotype, participants whose BMI 
was within the normal range had lower TG values than participants with a BMI in the overweight 
or obese category. Interestingly, in the underweight group, the influence of rs4917 on circulating 
TG was opposite that of the overweight/obese group. Although the sample size is very limited 
(n=46), it appears that underweight AHSG T-carriers had lower TG values than underweight CC-
homozygotes. AHSG rs4917 was not associated with total cholesterol, HDL or LDL. Rs2518136 
genotypes were not associated with TG.  
3.4 Discussion 
To our knowledge, we are the first to investigate AHSG polymorphisms and obesity parameters in 
a Mexican population. No association was found between AHSG SNPs and BMI or WC in either 
the cross-sectional or in the longitudinal cohort. AHSG polymorphisms were, however, correlated 
with fasting FetA and TG. 
Previous findings agree that the AHSG rs4917 T-allele promotes lower circulating values of FetA 
but found that this SNP site explained around 21% of the variance in FetA (105). Jensen and 
collaborators found that T-allele carriers of rs4917 in Caucasian and African American populations 
had 13% and 11% lower circulating FetA, respectively (106). In our cohort, we found that rs4917 
genotype explained 8% of the variance in circulating FetA. The rs4917 T-allele was associated 
with an 8% decrease in FetA. In sum, Mexican adults had an average 30.0 µg/mL decrease in FetA 
per minor allele at rs4917. Each T-allele at rs2518136 was also associated with a 32.5 µg/mL 
decrease in FetA. Therefore, the decrease in FetA per rs4917 T-allele is lower in our Mexican 
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cohort as compared to other cohorts suggesting that individual variability may also be influenced 
by other behavioral and biological factors beyond genetics. 
When compared to Caucasian and African American cohorts, there are significant differences in 
the MAF of these two SNPs in Hispanic cohorts (106). The frequency of the minor T-allele at 
rs4917 in Mexican adults is 41.4% which makes it more common than in Caucasian and African 
American cohorts (33% and 30%, respectively). Therefore, if rs4917 genotypes were the main 
driver of circulating FetA, it would be expected that on average Hispanics have lower circulating 
FetA than Caucasians. The same inference could be made for rs2518136 because of differences in 
the minor alleles for populations of Hispanic and Caucasian origin. However, we found that 
circulating FetA and the variability explained by rs4917 genotypes was lower in Mexican adults 
than in previous reports of differing ethnicities.  
In Caucasians, the T-allele is the minor allele at rs2518136. However, in our cohort of Mexican 
adults, the minor allele is the C-allele (46%). Thus the risk allele (T) is more common in our 
sample. Rs2518136, a tag SNP for rs2070633 and rs2070635, was related to circulating FetA. The 
T-allele at AHSG rs2070633 and the A-allele at AHSG rs2070635 were linked to lower levels of 
FetA (105). Therefore it is not surprising that the T-allele at rs2518136, is associated with lower 
FetA. However, it is of interest that this allele is more common in the Mexican population.  
Based on these data, it would be expected that Mexican Adults should have lower circulating FetA 
in comparison to other ethnicities. However, unpublished data from our lab as well as the results 
of other research teams have not found this to be the case. Using the same methodology, our lab 
has found that average FetA was 286.2±61.5 µg/mL in an age-matched cohort of 54 Caucasian 
students at the University of Illinois (Appendix 1). In the longitudinal arm of the UP-AMIGOS 
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cohort, we report average FetA values of 368.4±89.8 µg/mL. One study found that FetA tended to 
be lower in Hispanics than Caucasians, but this did not reach statistical significance (139). 
Therefore, other biological and behavioral/environmental factors may be more influential in 
determining circulating FetA in Hispanic populations.  
We found no association between AHSG rs4917 and HOMA-IR. A similar study by Jensen et al. 
found no association between AHSG rs4917 and incident T2DM or fasting glucose concentration 
in Caucasian and African American adults (106). Our data revealed that the T-allele at rs4917 was 
associated with higher fasting TG values in a sample of young Hispanic adults. This association 
has not been reported in Caucasian cohorts (109,133). Mexican populations have a higher 
frequency of the T-allele than Caucasian populations. This base mutation at rs4917 results in an 
amino acid change (Thr230Met) thus, may alter the tertiary structure of FetA and alter the ability 
of FetA to bind receptors. 
As an intronic SNP, rs2518136 is not translated into the final protein. Yet, intronic SNPs may 
impact mRNA promoter binding, splicing, and transcription (140). Andersen et al. reported that 
rs2518136 was associated with T2DM. Contrary to our findings, the T-allele was more common 
in individuals with T2DM in this cohort (133). Jensen and colleagues noted no association of 
rs2518136 with markers of diabetes (106). We found no association of AHSG SNP with fasting 
glucose or HOMA-IR. These contradictory findings may be explained by the ethnic differences of 
our cohorts as allele frequencies differ among ethnic groups.  
Our cohort included mainly healthy, young adults and therefore, other cohorts with poorer health 
or older age may yield different conclusions. Attending college represents a unique transition in 
an adult’s life which may include significant dietary and exercise changes. Therefore, follow-up 
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of this cohort is ongoing with consideration for dietary intake. As weight gain progresses due to 
age and lifestyle changes, it is possible that genetic associations will shift. Dietary intake, 
specifically fat consumption, has been shown to significantly influence the association of SNPs 
with circulating lipid values (141). As mentioned previously, AHSG is located in 3q27. This is a 
diabetes-susceptible locus and has also been shown to influence macronutrient and total calorie 
intake (104). Thus, it is possible that the association of rs4917 and triglycerides is mediated by 
dietary intake. A limitation of this study was the relatively small number of samples available for 
the analysis of plasma FetA. Furthermore, other biological or behavioral differences between the 
genotype groups in our longitudinal cohort, cannot be ruled out. 
3.5 Conclusion 
In conclusion, individual genetic variants in the AHSG gene impact triglycerides and circulating 
FetA. Our study is the first to describe these markers in a young Mexican population, which has 
differing minor allele frequencies than Caucasian populations. Our results suggest that 
maintenance of a healthy body weight may overcome the deleterious effects of genes related to 
MetS and T2DM. These findings demonstrate an important public health message, that even in the 
face of genetic predisposition, health biomarkers may be modified by health behaviors.   
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Table 3.1. Minor Allele Frequency (MAF) of AHSG SNPs reported in the 1000 Genomes 
Project and in the UP-AMIGOS cohorts 
SNPs 
1000 Genomes Project  
UP-AMIGOS 
Cohort 
 
UP-AMIGOS 
Longitudinal 
CEU MXL  MEX  MEX 
N 99 64  714  75 
rs4917 0.33 (T) 0.41 (T)  0.425 (T)  0.50 (T) 
rs2518136 0.49 (T) 0.46 (C)  0.460 (C)  0.44 (C) 
Populations reported include: MXL, Mexican Ancestry from Los Angeles. CEU, Utah residents with North and 
Western European Ancestry. MEX, Mexican adults living in Mexico from the Universities of San Luis Potosí and 
Illinois: A Multidisciplinary Investigation on Genetics, Obesity, and Social-environment (UP-AMIGOS) Project. 
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Table 3.2. Demographic Variables by Sex of the UP-AMIGOS Cohort 
Variable N   Males N Females p-value 
 
Age (years) 312 19.1 ± 2.3 405 19.0 ± 2.1 0.48  
BMI (kg/m2) 312 24.5 ± 4.5 405 23.6 ± 4.7 0.009  
Waist Circumference (cm) 304 84.2 ± 11.3 396 77.8 ± 11.6 <0.0001  
GLC (mg/dL) 312 92.0 ± 8.0 405 88.0 ± 8.3 <0.0001  
TG (mg/dL) 267 118.1 ± 57.8 351 106.4 ± 52.5 0.002  
TC (mg/dL) 264 170.2 ± 32.4 346 172.5 ± 37.4 0.43  
LDL (mg/dL) 247 99.9 ± 27.5 325 99.0 ± 28.9 0.65  
HDL (mg/dL) 251 47.2 ± 11.5 328 51.8 ± 11.8 <0.0001  
HOMA-IR 65 1.6 ± 1.2 64 1.8 ± 1.5 0.10  
Fetuin-A (µg/mL) 21 373.0 ± 82.2 34 366.5 ± 96.4 0.74  
Values are presented as means ± SD. p-values greater than 0.05 are considered statistically significant. 
Abbreviations: BMI: Body Mass Index; GLC: Glucose; TG: Triglycerides; TC: Total Cholesterol; LDL: Low 
Density Lipoprotein; HDL: High Density Lipoprotein; HOMA-IR: Homeostatic Model Assessment for Insulin 
Resistance. 
 
 
 
 
  
Table 3.3. Association of AHSG rs4917 and body mass index in the UP-AMIGOS cohort 
  
Variables 
rs4917 p-value for the 
additive model 
(CC vs. TC vs. 
TT) 
p-value for the 
recessive model 
(CC vs. TC/TT) 
p-value for the 
dominant model 
(CC/TC vs. TT) 
CC TC TT 
Sex (male/female)         93/137       163/202 56/66    
Age (years) 18.8 ± 0.1 19.3 ± 0.1 18.9 ± 0.2 0.017a 0.018a 0.452a 
BMI (kg/m2) 23.7 ± 0.3 23.4 ± 0.2 23.83 ± 0.4 0.821b 0.737b 0.690b 
Waist Circumference (cm) 80.6 ± 0.8 81.1 ± 0.6    81.6 ± 1.0 0.735b 0.485b 0.580b 
GLC (mg/dL) 90.2 ± 0.5 89.7 ± 0.4 89.4 ± 0.7 0.631c 0.381c 0.518c 
TG (mg/dL) 100.2 ± 2.9 100.7 ± 2.4 110.4 ± 4.4 0.058c 0.263c 0.018c 
TC (mg/dL) 166.9 ± 2.3 167.6 ± 1.9 172.0 ± 3.2 0.339c 0.413c 0.155c 
LDL (mg/dL) 97.5 ± 2.0 96.7 ± 1.6 100.0 ± 2.8 0.602c 0.878c 0.321c 
HDL (mg/dL) 48.9 ± 0.8 49.0 ± 0.7 48.0 ± 1.1 0.775c 0.743c 0.480c 
HOMA-IR 1.4 ± 0.2 1.3 ± 0.1 1.4 ± 0.2 0.748c 0.471c 0.993c 
Values are presented as means ± se. ap-values were adjusted by sex. bp-values were adjusted by sex and age. cp-values were adjusted by sex, age and BMI. 
Abbreviations: BMI: Body Mass Index; GLC: Glucose; TG: Triglycerides; TC: Total Cholesterol; LDL: Low Density Lipoprotein; HDL: High Density 
Lipoprotein; HOMA-IR: Homeostatic Model Assessment for Insulin Resistance. 
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Table 3.4. Association of AHSG rs2518136 and body mass index in the UP-AMIGOS cohort 
Variables 
rs2518136 p-value for the 
additive model 
(CC vs. TC vs. 
TT) 
p-value for the 
recessive model 
(CC vs. TC/TT) 
p-value for the 
dominant model 
(CC/TC vs. TT) CC TC TT 
Sex (male/female) 64/83 155/210 93/112    
Age (years) 18.8 ± 0.1 19.2 ± 0.1 19.0 ± 0.2 0.110a 0.065a 0.721a 
BMI (kg/m2) 23.9 ± 0.4 23.6 ± 0.2 23.7 ± 0.3 0.754b 0.455b 0.869b 
Waist Circumference (cm) 80.2 ± 1.0 81.3 ± 0.6 81.2 ± 0.8 0.598b 0.312b 0.811b 
GLC (mg/dL) 91.5 ± 0.7 89.6 ± 0.4 89.4 ± 0.6 0.521c 0.299c 0.432c 
TG (mg/dL) 98.1 ± 3.6 102.8 ± 2.4 104.0 ± 3.2 0.241c 0.102c 0.355c 
TC (mg/dL) 165.1 ± 2.9 169.0 ± 1.9 168.8 ± 2.5 0.334c 0.138c 0.632c 
LDL (mg/dL) 97.1 ± 2.5 98.7 ± 1.6 96.0 ± 2.1 0.560c 0.628c 0.453c 
HDL (mg/dL) 48.2 ± 1.0 48.9 ± 0.7 48.8 ± 0.9 0.935c 0.779c 0.895c 
HOMA-IR 1.6 ± 0.2 1.2 ± 0.1 1.5 ± 0.2 0.078c 0.047c 0.671c 
Values are presented as means ± se. ap-values were adjusted by sex. bp-values were adjusted by sex and age. cp-values were adjusted by sex, age and BMI. 
Abbreviations: BMI: Body Mass Index; GLC: Glucose; TG: Triglycerides; TC: Total Cholesterol; LDL: Low Density Lipoprotein; HDL: High Density 
Lipoprotein; HOMA-IR: Homeostatic Model Assessment for Insulin Resistance. 
 
  
Table 3.5. Body composition changes in the UP-AMIGOS Longitudinal cohort by AHSG genotype (n=74)    
Variables 
rs4917 p-value 
(CC vs. 
TC vs. 
TT) 
p-value 
(CC vs. 
TC/TT) 
p-value 
(CC/TC  
vs. TT) 
rs2518136 p-value 
(CC vs. 
TC vs. 
TT) 
p-value  
(CC vs. 
TC/TT) 
p-value 
(CC/TC  
vs. TT) 
CC TC TT CC TC TT 
N 18 39 17   
 
14 38 22   
 
Fetuin-A(µg/mL) 393 ± 23      368 ± 16 319 ± 23 0.069a 0.145a 0.029a 396 ± 27 376 ± 16 319 ± 20 0.045a 0.142a 0.017a 
Body Weight Δ (%)      7.4 ± 11.4 8.9 ± 10.3   7.8 ± 8.1 0.875b 0.373b 0.836b     6.2 ± 11.0   10.1 ± 10.1   6.3 ± 8.8 0.327b 0.412b 0.367b 
BMI Δ(kg/m2)      1.1 ± 2.7 1.7 ± 2.7  1.5 ± 1.7 0.698b 0.439b 0.918b   0.9 ± 2.7   2.0 ± 2.8   1.2 ± 1.8 0.316b 0.272b 0.537b 
WC Δ(cm)    -1.7 ± 9.8 0.8 ± 8.5 -0.3 ± 7.7 0.892b 0.750b 0.808b   -1.3 ± 10.0   1.2 ± 8.5 -1.6 ± 7.8 0.726b 0.997b 0.448b 
Values are presented as means ± se. ap-values were adjusted by sex, BMI and age. bp-values were adjusted by sex and age. Abbreviations: BMI: Body Mass 
Index; WC: Waist Circumference. 
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Figure 3.1. Individual variation in AHSG SNP (rs4917) was associated with triglycerides in 
the UP-AMIGOS cohort. C/C homozygotes and heterozygotes had significantly lower triglyceride 
values than T/T homozygotes (p=0.048 and p=0.045, respectively). Error bars represent the standard error 
of the mean. 
 
  
80
90
100
110
120
C/C C/T T/T
N=203 N=308 N=107
C
ir
cu
la
ti
n
g
 T
ri
g
ly
ce
ri
d
es
 (
m
g
/d
L
)
rs4917 Genotype
0
*
*
41 
 
 
Figure 3.2. The association of AHSG SNP (rs4917) with triglycerides was modified by body 
mass index (BMI) category. Individuals that were T/T homozygotes and were overweight or obese had 
significantly higher triglycerides than C/C homozygotes who were overweight or obese (p=0.029). 
Conversely, T/T homozygotes who were underweight had significantly lower triglycerides (56.9 ± 7.3 
mg/dL) than carriers of C/T (82.2 ± 5.4 mg/dL) and C/C (97.2 ± 7.5 mg/dL) alleles who were underweight 
(p=0.018 and p=0.0008, respectively). Individuals with a BMI in the normal range had no significant 
differences in triglycerides between genotypes. Error bars represent the standard error of the mean. 
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CHAPTER 4. CIRCULATING FETUIN-A DECREASES DURING 
PREOPERATIVE CALORIE RESTRICTION AND FOLLOWING SLEEVE 
GASTRECTOMY 
 
Abstract  
Background: Bariatric surgery is an effective treatment for both obesity and type 2 diabetes 
mellitus (T2DM). Glucose homeostasis is restored within days of surgery independent of weight 
loss. The hepatokine, Fetuin-A (FetA), has been suggested to play a role in diabetes remission 
since it dramatically decreases following bariatric surgery. It is unclear why FetA decreases 
postoperatively and the impact of the preoperative diet has not been previously investigated.  
Methods: Plasma was collected from sleeve gastrectomy patients (n=39) before the preoperative 
diet, on the day of surgery and approximately six weeks postoperatively. At each visit, body 
composition was collected via bioelectrical impedance analysis.  
Results: FetA decreases 12% from baseline to day of surgery (606±170 μg/mL vs. 533±99 μg/mL, 
p=0.010). Compared to baseline, average FetA was 35% lower following the postoperative diet 
(392±83 μg/mL, p<0.0001). Although weight loss was significant in both sexes, the total change 
in FetA was associated with percent body weight loss in women only (r=0.39, p=0.03). 
Conclusions: The reduction in FetA following bariatric surgery begins during the preoperative 
diet phase. Therefore, immediate improvements in glucose homeostasis may be partly explained 
by preoperative caloric restriction. Future studies which seek to evaluate metabolic improvements 
occurring within days of bariatric surgery should disclose whether participants completed a 
hypocaloric, preoperative diet.  
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4.1 Introduction 
Bariatric procedures result in significant weight loss and resolution of obesity-associated diseases. 
In 2013, 468,609 patients with morbid obesity opted for surgical treatment of obesity. The 
procedure that is growing most rapidly in popularity is the sleeve gastrectomy (SG) which 
accounted for 37% of all surgeries (42). SG patients lose an average of 62.3% of excess body 
weight five years after surgery (142). Resolution rates for type 2 diabetes mellitus (T2DM) are 
near 80% for SG (43–45). Thus, important insights about the pathophysiology of T2DM and novel 
markers of glucose homeostasis may be gained from understanding the mechanisms behind SG 
outcomes. 
The hepatokine, Fetuin-A (FetA), reduces significantly after bariatric surgery, therefore, it has 
emerged as a potential novel marker of glucose homeostasis improvements. FetA has been 
suggested to play a role in glucose metabolism through two mechanisms: 1) FetA inhibits insulin 
receptor autophosphorylation, therefore, limiting translocation of the glucose transporter (GLUT 
4) and 2) when bound to saturated fatty acids, FetA can signal the inflammatory cascade through 
toll-like receptor 4, thus promoting insulin resistance (81,98). Increased FetA has been linked to 
adverse health conditions including T2DM and CVD (82,84,120). Thus, FetA reductions 
following surgery may explain some of the immediate improvements in glucose homeostasis 
following bariatric procedures.  
To date, three studies have evaluated changes in FetA following weight loss surgery. Although 
study lengths and protocols varied, all found that when compared to preoperative FetA, 
postoperative FetA was significantly lower. Sixteen months after Roux-en-Y Gastric Bypass 
(RYGB), average BMI was decreased by 34% and FetA decreased by 19% (143). FetA was also 
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significantly reduced one year after RYGB, mini-gastric bypass, and SG. Overall, the average 
change was 10% but the largest change (near 14%) was seen in the group receiving SG (119). In 
a metabolomic analysis, FetA was one of only two proteins to significantly decrease three days 
after RYGB when compared to three days before surgery. In this short time period, plasma FetA 
decreased by 27% in the absence of significant weight loss (116). These studies suggest that 
bariatric procedures result in the rapid and sustained reduction of FetA. However, it is unclear 
whether this reduction in FetA is unique to surgery or can be partially explained by dietary 
restriction.  
Circulating FetA responds to dietary changes. Exposure to high-fat diets increased FetA in vitro 
and in animal models (144). Hepatocytes exposed to saturated fatty acids; specifically palmitate, 
secreted FetA in a dose-dependent manner and had higher expression of FetA mRNA (145). FetA 
is also reduced by caloric restriction (113). Thus, when attempting to study the response of FetA 
to surgery, it is important to consider the role of the diet. 
In the weeks preceding bariatric surgery, patients are often prescribed a hypocaloric, low-fat diet. 
The preoperative diet is recommended to decrease liver size and thus, improve access to the 
stomach and gastro-esophageal junction (146). In the three studies mentioned previously 
(112,116,119), the timing of the initial FetA measurement was often unreported except one, which 
measured baseline FetA three days before surgery (116). Details about the preoperative diet 
protocol were also not consistently described. Thus, the patient’s baseline FetA level may have 
already been influenced by preoperative diet regimen. Therefore, our objective is to describe 
changes in FetA during the preoperative diet as well as the weeks immediately following SG. 
45 
 
4.2 Methods  
Data Collection 
Forty-five patients receiving SG at Carle Foundation Hospital (Urbana, IL) were recruited for the 
longitudinal cohort. Patients were excluded if they were current smokers, below the age of 18 or 
had a pacemaker or implanted defibrillator. Participants attended three visits; baseline (T0) took 
place approximately two weeks (median: 18 days, mode: 15 days) before surgery prior to the 
preoperative diet. The second appointment (T1) occurred following the two-week preoperative 
diet on the morning of surgery. The final appointment (T2) occurred approximately six-weeks 
(median: 41 days, mode: 41 days) following surgery. The Individual Outcomes of Weight Loss 
Surgery (I-OWLS) Study protocol received approval from the Institutional Review Boards at both 
Carle Foundation Hospital and the University of Illinois at Urbana-Champaign. 
A Registered Dietitian Nutritionist advised each patient on the pre- and postoperative dietary 
protocol. During the two weeks before surgery, men were advised to consume 1000 calories and 
70-90 grams of protein per day. Women were advised to consume 800 calories and 50-60 grams 
of protein per day. All patients were encouraged to drink 64 ounces of water each day and to split 
daily calories into six small meals. The postoperative diet was a standard transitional diet: full 
liquid for postoperative weeks 1-2, pureed diet for postoperative weeks 3-4 and regular foods 
during postoperative week 5. Three-day food logs (including two weekdays and one weekend day) 
were collected at each appointment to assess dietary adherence. Food logs were analyzed using the 
Nutrition Data System for Research software developed at the University of Minnesota (147). 
Participants were asked to arrive at each appointment fasted, to avoid alcohol for 24 hours prior to 
the visit and to avoid exercise for 12 hours prior to the visit. All completed a survey which inquired 
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about demographic variables and medical history. Height, weight and body composition 
(InBody230, Biospace, Cerritos, CA) were measured by trained research staff (K.R.). 
Laparoscopic SG was performed by one of two surgeons (B.R. and U.O.) at Carle Hospital 
following protocols previously established at the Carle Bariatric Surgical Unit.  
Blood analysis 
Fasting blood was collected by trained phlebotomists at Carle Hospital. Blood was centrifuged 
within 30 min at 10,000g for 10min, separated into aliquots and stored at -80°C until further 
analysis. Plasma FetA and insulin were measured by enzyme-linked immunosorbent assays 
(ELISA) (BioVendor™, Asheville, NC and EMD Millipore, Billerica, MA). Blood lipids were 
measured by LabCorps (Dublin, OH) and glucose was measured in duplicate by glucometer 
(Trividia Health, Fort Lauderdale, FL). Homeostatic Model Assessment for Insulin Resistance 
(HOMA-IR) was calculated using Matthews’ equation (138). 
Statistics  
Variables were evaluated for errors and normality. Non-normal variables were transformed for 
analysis and back-transformed for interpretation. The effect of preoperative diet and SG on FetA 
was assessed by calculating the change (Δ) between T0 and T1 and between T1 and T2 
appointments, respectively. Total weight loss was calculated during the preoperative diet, during 
the postoperative diet and across the entire study length using BMI. Ideal body weight was 
estimated based on a reference BMI of 25 kg/m2 and used to calculate excess weight (EBW) at 
baseline and excess weight loss percentage at T1 and T2. To assess rate, FetA change was averaged 
over the days between appointments. Time was treated as a within-subject factor. Thus, repeated 
measures of time were considered. Differences between time points were compared using mixed 
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models and contrast statements as appropriate. All statistical analysis was performed in SAS 9.4 
(Cary, NC). 
4.3 Results  
Demographics 
The study protocol was completed by 39 participants (80% female) (Table 4.1, Fig. 4.1), of which, 
86.8% were non-Hispanic white and 13.2% were non-Hispanic black. Average baseline BMI was 
47 kg/m2 and baseline percent body fat (PBF) was 52% for females and 47% for males. Prediabetes 
or T2DM diagnosis was reported by 30% of participants. Baseline average calorie intake was 
1757±121 kcal per day with a macronutrient distribution of 43% carbohydrate, 19% protein and 
38% fat. When stratified by sex, the only significant difference was greater (p=0.04) fat 
consumption in men (42±7.3%) when compared to women (37±6.3%). 
Caloric intake, excess weight and HOMA-IR were significantly reduced during the pre- and 
postoperative period. 
Dietary intake differed (p<0.0001) across time points. During the preoperative and postoperative 
diet, intake decreased to 960±42 and 751±54 calories per day, respectively. No sex differences 
were found in reported dietary intake at either T1 or T2. Macronutrient distribution of the 
preoperative diet was 61% carbohydrate, 24% protein and 15% fat whereas distribution at six-
week follow-up was 34% carbohydrate, 31% protein and 35% fat (Fig. 4.2). 
Significant weight change was observed during the study (Table 4.2). Following the preoperative 
diet, men lost 10.8±3.3% of EBW while women lost 9.9±4.6% of EBW. On average, postoperative 
EBW loss was 19.5±8.5% in men and 18.2±6.9% in women. During the preoperative diet, 
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significant improvements in fasting HOMA-IR were noted (p<0.0001). At baseline, average 
HOMA-IR was 2.75±0.26. On the morning of surgery, HOMA-IR was 1.15±0.11. At six-week 
follow-up, average HOMA-IR was not significantly lower than on the morning of surgery 
(1.12±0.10, p=0.797). 
Response of circulating FetA to the preoperative diet and sleeve gastrectomy 
FetA was significantly reduced during both the preoperative diet and during the six-weeks 
following surgery (Fig. 4.3). At baseline, average FetA was 589.7±113.5 μg/mL in males and 
610±185 μg/mL in females (p=0.620 for sex). Older age was associated with lower baseline FetA 
in women only (r= -0.52, p=0.004). Baseline FetA change was not significantly correlated with 
sex, HOMA-IR, BMI or PBF. Following the hypocaloric, preoperative diet, FetA declined from 
baseline in both men (491.9±79.1 μg/mL) and women (545.8±101.83 μg/mL). At T1, FetA tended 
(p=0.052) to be lower in men. In both sexes, the change in FetA was associated with baseline FetA, 
in that; those with the highest baseline FetA had the greatest reductions in FetA during the 
preoperative diet (r=0.69, p<0.0001). In women, preoperative FetA change was significantly 
correlated with percent weight change (r=0.39, p=0.03), BMI change (r=0.38, p=0.04) and EBWL 
(r=0.37, p=0.04), but not with PBF change or time between T0 and T1. In men, preoperative FetA 
change was not significantly associated with any of the aforementioned weight variables (Fig. 4.4, 
A-B) (Appendix 3). 
Following surgery, FetA further decreased to 367.7±85.7 in males and 399.9±85.7 in females 
(p=0.433). In women, this change was related to BMI change (r=0.48, p=0.008) and body weight 
percentage (r=0.43, p=0.018) change. Again, change in FetA in males was not related to change 
in body composition (Fig. 4.4, C-D). FetA changes during the postoperative period were correlated 
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with changes during the preoperative diet (r= -0.53, p=0.0005). Additionally, the rate of FetA 
reduction (total FetA change divided by the time interval in days) was not significantly different 
during the pre- and postoperative periods. FetA and HOMA-IR were not associated at baseline or 
on the day of surgery. However, HOMA-IR at T0, T1 and T2 were significantly associated with 
FetA at follow-up (p=0.002, 0.003 and 0.001, respectively) (Table 4.3, Fig. 4.5). 
Circulating FetA was not associated with reported caloric intake or macronutrient distribution at 
baseline or during the preoperative diet. During the postoperative diet, individuals who had greater 
reductions in dietary fat had greater reductions in FetA (r=0.35, p=0.039). This association was 
strongest in women (r=0.43, p=0.027). No further correlations with caloric intake or macronutrient 
distribution were observed during the postoperative diet. 
4.4 Discussion 
The preoperative diet regimen offers an important period for studying how individuals with morbid 
obesity respond to acute dietary changes prior to receiving weight loss surgery. However, the 
literature often fails to account for this time period. In the case of FetA, we found that FetA was 
significantly reduced following the preoperative diet and during the weeks immediately following 
SG. Although the time period during the preoperative diet and the postoperative period differed, 
the rate of FetA change was not significantly different. In females only, FetA change was 
associated with change in BMI, but not with change in body composition as measured by 
bioelectrical impedance. Caloric intake was significantly reduced over the course of this study. 
However, calories alone did not explain changes in circulating FetA. Some evidence emerged to 
suggest that dietary fat intake is correlated with postoperative FetA in females, but replication is 
needed. Although the pre- and postoperative diets both allow additional calories for men, there 
50 
 
was no reported difference in daily caloric intake between the sexes. Food logs may be limited due 
to reporting errors or bias. 
It remains unclear why FetA reduces following bariatric surgery. In women, change in BMI, age 
and baseline FetA were associated with greater reductions in FetA. Although pre- and 
postoperative FetA changes were not associated with changes in dietary intake, we have 
demonstrated the importance of monitoring changes during the preoperative period. A consistent 
association between FetA and HOMA-IR was not seen at each time point, though we did observe 
that HOMA-IR at baseline, on the morning of surgery and at follow-up was significantly associated 
with postoperative FetA. Specifically, higher HOMA-IR at these time points predicted lower FetA 
at six-week follow-up. Other potential mechanisms for the reduction in FetA include changes in 
liver composition and hepatic functioning that were not measured in this cohort.  
Like other studies of bariatric patients, our sample was primarily female. Further studies in male 
populations are warranted. Phosphorylated forms of FetA were not accessed, but may yield a 
different response to surgery and may be a more sensitive indicator of FetA function. Nevertheless, 
our results suggest that the preoperative diet should be considered during the study of bariatric 
outcomes. We found that FetA, a marker of relevance to T2DM which quickly improves following 
surgery, actually begins to improve preoperatively. Thus, it should be standard procedure for all 
studies in this area to report whether preoperative diets were completed, as well as the duration 
and composition of the preoperative diet.  
4.5 Conclusion  
Metabolic and longitudinal cohort reports have found that FetA decreases after bariatric surgery 
and therefore may account for immediate improvements in insulin sensitivity (112,116,119). 
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However, preoperative diet protocol is not considered or not reported in these studies. We found 
that the reduction in FetA following bariatric surgery is already present following the preoperative 
diet. FetA reduction is most strongly correlated with baseline FetA as well as HOMA-IR at all 
previous time points. Therefore, improvements in circulating FetA may be partly explained by 
behavioral modifications that occur prior to SG. The preoperative diet offers an opportunity to 
evaluate the impact of a behavioral intervention on outcomes of interest in post-bariatric glucose 
improvements. Studies reporting short-term improvements in glucose homeostasis should disclose 
whether patients were or were not advised to complete a preoperative dietary restriction.  
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Figure 4.1. Participant flow diagram for the I-OWLS cohort. Participants were recruited June 
2015 through March 2016. Of the 45 individuals who were consented for the study, 89% completed all 
three scheduled appointments. 
 
 
  
42 visits on the 
day of surgery 
(T1) 
45 consented 
44 initial visits 
(T0) prior to 
preoperative 
diet 
1 participant opted out of surgery 
2 participants switched to another 
bariatric procedure prior to surgery 
1 participant opted out of surgery 
1 lost to follow-up 
 40 follow-up 
visits six-weeks  
after surgery (T2) 
1 did not have plasma available for 
analysis 
39 available for 
analysis of 
FetA 
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Table 4.1. Baseline characteristics of the I-OWLS cohort  
Variable Females Males p-value 
N 31 9  
Age (years)   43.7 ± 1.7 45.8 ± 3.3 0.58 
BMI (kg/m2)   47.4 ± 1.2 46.9 ± 2.7 0.85 
Percent Body Fat   52.1 ± 0.5 46.9 ± 2.2 0.0009 
TG (mg/dL)   149.3 ± 14.3 137.9 ± 17.7 0.69 
TC (mg/dL) 180.3 ± 6.9 160.7 ± 10.5 0.18 
HDL (mg/dL)   43.5 ± 2.5 35.0 ± 2.7 0.11 
LDL (mg/dL) 108.5 ± 6.1   98.2 ± 10.5 0.42 
Glucose (mg/dL) 103.4 ± 2.4    107.8 ± 1.78.1 0.56 
HOMA-IR     2.8 ± 0.6   2.8 ± 0.3 0.92 
Fetuin-A (µg/mL)   611.0 ± 33.8 589.7 ± 37.8 0.75 
Values are presented as means ± SE. p-values greater than 0.05 are considered statistically significant. 
Abbreviations: BMI: Body Mass Index; TG: Triglycerides; TC: Total Cholesterol; LDL: Low Density Lipoprotein; 
HDL: High Density Lipoprotein; HOMA-IR: Homeostatic Model Assessment for Insulin Resistance. 
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Table 4.2. Weight loss trajectory of the I-OWLS cohort 
Variable Females (n=31) Males (n=9) 
p-value for change 
between time points 
adjusted by sex 
  T0 T1 T2 T0 T1 T2   
Age (years)    43.2 ± 1.7   43.3 ± 1.8     43.3 ± 1.8   45.8 ± 3.3   45.6 ± 3.3   45.9 ± 3.2 NS 
Weight (kg) 131.9 ± 3.9 125.9 ± 3.8 115.1 ± 3.5 148.2 ± 8.4 141.3 ± 7.9 127.6 ± 7.7 <0.0001 
BMI (kg/m2)   47.3 ± 1.2   45.2 ± 1.2   41.3 ± 1.1   46.9 ± 2.7   44.7 ± 2.6   40.5 ± 2.5   0.0007 
Body Fat (%)   52.1 ± 0.5   52.3 ± 0.6   50.2 ± 0.7   46.9 ± 2.2   46.0 ± 2.7   43.5 ± 2.7 <0.0001 
Values are presented as means ± SE. Change across time was analyzed using generalized linear model adjusted for sex. p-value less than 0.05 are considered 
statistically significant. Abbreviations: BMI: Body Mass Index.  
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Figure 4.2. Reported macronutrient distribution range of sleeve gastrectomy patient by visit. 
Three-day dietary records were collected from participants at each visit. Logs were analyzed in Nutrition 
Data System for Research software. Macronutrient distribution was calculated by dividing average total 
calories of fat, protein and carbohydrate by average daily caloric intake. 
T0 T1 T2
Fat 38 15 35
Carbohydrate 43 61 34
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Figure 4.3. Fasting plasma Fetuin-A concentrations in sleeve gastrectomy patients at 
baseline (T0), on the morning of surgery (T1) and at six-week follow-up. Fasting plasma 
Fetuin-A was significantly reduced on the morning of surgery and at six-week follow-up compared to 
baseline. Data are adjusted for age and presented as mean ± SE.  
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Figure 4.4. Correlation of fetuin-A change with body mass index (BMI) change during the 
pre- and postoperative period by sex; A. preoperative correlation in females; B. preoperative 
correlation in males; C. postoperative correlation in females; D. postoperative correlation in males. p-value 
less than 0.05 are considered statistically significant. 
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Table 4.3. Correlation of HOMA-IR and Fetuin-A by visit 
Variable Fetuin-A 
    T0 T1 T2 
H
O
M
A
-I
R
 
T0 
r= -0.27 r= -0.13 r= -0.48 
p=0.111 p=0.427 p=0.003 
T1 
r= -0.33 r= -0.23 r= -0.47 
p=0.044 p=0.168 p=0.003 
T2 
r= -0.30 r= -0.14 r= -0.50 
p=0.068 p=0.420 p=0.001 
Associations were evaluated using Pearson Correlation Coefficient. p-value 
less than 0.05 are considered statistically significant.  
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Figure 4.5. Correlation of postoperative Fetuin-A with HOMA-IR; A. at baseline; B. on the 
morning of surgery; C. at six-week follow-up.  
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CHAPTER 5. ADIPOCYTE SIZE, CIRCULATING FETUIN-A AND 
SURGERY-INDUCED WEIGHT LOSS IN INDIVIDUALS WITH INSULIN-
RESISTANT OBESITY AND INSULIN-SENSITIVE OBESITY 
 
Abstract  
Background: Although excess adiposity is associated with increased risk for diabetes, there is a 
subset of adults who remain insulin-sensitive in the face of morbid obesity. Although consensus is 
limited, cross-sectional studies have elucidated several behavioral and biological factors including 
the hepatokine Fetuin-A (FetA), which may differentiate individuals with insulin-resistant obesity 
(Obres) from their insulin-sensitive (Obsen) counterparts. It is unclear whether these groups respond 
differently to sleeve gastrectomy (SG), a weight loss surgery which leads to improved insulin 
sensitivity and sustained weight loss.  
Methods: Candidates for SG (n=40) were evaluated at baseline (T0), on the morning of surgery 
(T1) and six weeks following SG (T2). Three-day food logs, body composition data and fasting 
blood for the measurement of FetA, insulin, lipids and glucose were collected at each visit. 
Adipocyte diameter was calculated from omental adipose tissue collected during surgery. To 
compare Obres and Obsen, the cohort was divided into age- and sex-matched groups (n=10 each) 
based on homeostatic model assessment for insulin resistance values with consideration for 
diabetes diagnosis and use of anti-diabetic medications.  
Results: The Obsen group tended to have higher FetA than Obres at all time points (T0: p=0.09; T1: 
p=0.10 and T2: p=0.004). Baseline BMI did not differ between groups yet, the Obres group had 
greater total excess body weight loss (-29% vs. -26%, p= 0.01). Those with Obres had larger 
adipocytes than Obsen (71±2 vs. 61±3 µm, p=0.01). This relationship was exaggerated when 
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adjusting for genetic differences in toll-like receptor 4 (rs4986790). Adipocyte size was positively 
correlated with preoperative change in FetA (r=0.64, p=0.007) but not with changes in dietary 
intake, body fat loss or BMI loss. 
Conclusions: Participants with Obsen tended to have higher FetA at all time points. Greater 
reduction in FetA during the preoperative diet was associated with smaller adipocyte size on the 
day of surgery. Declining FetA may suggest reduction in adipocyte size which correlates with 
improved insulin sensitivity, however, longitudinal studies of histology changes are needed.  
5.1 Introduction 
Excess adiposity increases the risk of developing insulin resistance and T2DM. Four percent of 
individuals with a normal BMI have T2DM while 15% and 26% of individuals categorized as 
obese class II and class III have T2DM, respectively (148). As morbid obesity rates climb, parallel 
increases in T2DM incidence are also reported. Long-term consequences of T2DM include 
reduced quality of life, high financial burden and devastating health consequences such as renal 
failure, cardiovascular disease, and peripheral neuropathy (149–151). Fortunately, not all 
individuals with obesity demonstrate impaired glucose tolerance. To date, it is unclear why some 
with higher BMI experience delayed onset of T2DM or do not develop T2DM at all. Therefore, a 
greater understanding of those susceptible to T2DM may help facilitate more targeted healthcare 
interventions in at-risk individuals.  
Recently, the term “metabolically healthy obesity (MHO)” has been suggested to describe an 
individual who has a BMI greater than 30 kg/m2 with no additional metabolic abnormalities 
associated with MetS. Specific criteria for MetS have been defined by the Adult Treatment Panel 
III (ATP III) and include the presence of three or more of the following: elevated triglycerides, 
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high blood pressure, hyperglycemia, elevated waist circumference and reduced HDL cholesterol 
(152). Although this definition exists for MetS, the definition for categorizing MHO and 
metabolically unhealthy obesity (MUHO) is heterogeneous in the literature (153,154). For 
example, O’Connell et al. used presence of any MetS criteria to identify MUHO subjects while 
Meigs et al. used presence of three or more MetS criteria (ATP III) to identify MUHO subjects 
(155,156). The use of MetS criteria to define MHO/MUHO has also been challenged. Some 
research suggests that MHO is not a stable period and that MHO individuals tend to be younger 
(≤40 years old) and eventually transition into MUHO (32). Furthermore, because MetS includes a 
spectrum of diseases, it is difficult to compare phenotypes. Therefore, it has been proposed that 
individual diseases, such as insulin resistance, be considered rather than a cluster of diseases such 
as MetS. 
Epidemiological data suggests that nearly 25% of individuals with a BMI >35 kg/m2 retain normal 
glucose tolerance (insulin-sensitive obesity (Obsen)) (157). The definition of normal glucose 
tolerance in this study was based on a HOMA-IR values <75th percentile of participants without 
diabetes however, diagnostic criteria from the American Diabetes Association and glucose 
infusion rate >70 µmol/kg-1/min-1 have also been used (31,154). Individuals with obesity are 
considered insulin-resistant (Obres) if they meet diagnostic criteria from the American Diabetes 
Association, HOMA-IR is >75th percentile of participants without diabetes or glucose infusion rate 
<60 µmol/kg-1/min-1.  
Numerous factors have been investigated in an attempt to understand why some develop Obsen and 
others develop Obres. Thus far, there is evidence to suggest that Obres individuals have higher 
dietary fat intake than Obsen individuals (30). At a biological level, circulating adipokines, 
specifically FetA, and inflammatory cytokines tend to be higher in individuals with Obres while 
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circulating ghrelin is reduced in individuals with Obres (31,158). Characteristics of adipose tissue 
may also differ significantly. For example, individuals with Obres tend to have higher fat content 
in the liver, more visceral adipose, greater macrophage infiltration of visceral adipose tissue and 
larger adipocyte size (31,159,160).  
Adipocyte size is influenced by obesity status, metabolic health and genetic factors. Adipocyte 
size has been positively correlated with body fat percentage and insulin resistance (161,162). 
Change in adipocyte size may lead to altered expression of surface level receptors. For example, 
large adipocytes had three times more glucose transporter 4 (GLUT4) protein than small 
adipocytes (163). Large adipocytes also expressed 40 fold more P85 regulatory subunit of 
phosphatidylinositol 3-kinase (P85-PI3K) mRNA than small adipocytes (163). Expression of 
GLUT4 is upregulated by insulin receptor activation and p85 (when not bound to p110) inhibits 
PI3K, a downstream target of insulin receptor activation (164). Knockout of P85 in mice led to 
increased insulin sensitivity, thus elevated P85 in large adipocytes support the findings that larger 
cells are insulin-resistant (165,166). Although not yet evaluated, FetA may be associated with 
adipocyte size.  
FetA is a ligand for both insulin receptor and toll-like receptor 4 (TLR4), which are receptors of 
importance for determining adipocyte size. FetA alters the ability of p85-PI3K to bind IRS-1, thus, 
inhibiting insulin receptor action and preventing GLUT4 translocation to the cell wall (81). FetA 
may also influence adipocyte size via inhibition of peroxisome proliferator-activated receptor-γ 
(PPAR-γ) via Wnt3a signaling (167). Finally, FetA has been suggested to be elevated in 
individuals with obesity and T2DM (31). Thus, we sought to understand the relationship between 
circulating FetA and adipocyte size. Because larger adipocytes are associated with insulin 
resistance, a description of the association between circulating FetA and adipose hypertrophy may 
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clarify whether FetA has potential as a biomarker for insulin sensitivity (162). We hypothesize 
that circulating FetA and adipocyte size will differ based on presence of comorbidities. 
Specifically, we expect that individuals with Obres will show greater adipocyte size than Obsen. We 
also sought to gather preliminary data concerning the influence of individual gene variants on 
adipocyte size. We hypothesized that single nucleotide polymorphisms (SNPs) in key genes such 
as PPAR-γ, TLR4, Fat Mass and Obesity (FTO) associated-gene and FetA (AHSG) would alter 
adipocyte size. 
To date, most studies comparing Obsen and Obres groups have been cross-sectional in nature. It is 
unclear whether these groups respond differently to interventions that improve insulin sensitivity. 
Diabetes control can be improved with just 5-10% (168). A recent meta-analysis found that rate of 
weight loss on very-low-calorie and low-energy liquid formulas was similar in adults with Obsen 
and Obres (169). Bariatric surgery is a highly effective intervention for diabetes treatment that 
results in glucose improvements just days after surgery (170). It is unclear whether individuals 
with Obres respond differently to bariatric surgery than individuals with Obsen. We seek to 
understand whether the presence of Obsen or Obres influences longitudinal outcomes of SG 
including changes in BMI, PBF, FetA and HOMA-IR. We also aim to understand how 
preoperative changes in weight and diet associate with adipocyte size on the day of surgery. 
5.2 Methods  
Data Collection 
The Individual Outcomes of Weight Loss Surgery (I-OWLS) study consisted of SG candidates 
(n=40) which were recruited from the Carle Foundation Hospital according to protocol approved 
by the Carle Hospital Institutional Review Board. Participants were excluded if they were a current 
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smoker, pregnant or attempting to become pregnant, under the age of 18 or if they had a pacemaker 
or implanted defibrillator. All participants met with research staff before beginning a required 
hypocaloric, preoperative diet intended to reduce the liver size. Visits took place at baseline (T0), 
on the morning of surgery (T1) and approximately six weeks following surgery (T2). At each of 
the three time points, fasting blood, three-day dietary recall and anthropometric measures 
(InBody230, Biospace, Cerritos, CA) were collected.  
Laparoscopic SG was performed by one of two surgeons at Carle Hospital following protocols 
previously established at the Carle Bariatric Surgical Unit. During surgery, approximately 1-2 
grams of visceral adipose tissue was collected from the omentum along the greater curvature of 
the resected stomach. This adipose tissue was immediately fixed with formalin and paraffin-
embedded for histological analysis. 
Blood analysis 
Plasma FetA and insulin concentrations were detected by Enzyme-linked immunosorbent assay 
(ELISA) method (BioVendor, Asheville, NC and EMD Millipore, Bellerica, MA). Blood lipids 
were measured by LabCorps (Dublin, OH) and glucose was measured in duplicate by glucometer 
(Trividia Health, Fort Lauderdale, FL). Homeostatic Model Assessment for Insulin Resistance 
(HOMA-IR) was calculated using Matthews’ equation (138). Genomic DNA was extracted from 
whole blood using a commercially available kit (Gentra Puregene Blood Kit, Qiagen, CA) and 
genotyped using the Fluidigm® SNP genotyping platform at the Functional Genomic Unit of the 
W.M. Keck Center at the University of Illinois. Genotypes were assigned using the Fluidigm® 
Genotyping Analysis Software version 4.1.2 (San Francisco, CA) with a minimum of 95% 
confidence.  
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Tissue histology  
Omental adipose tissue was available from 30 participants. Formalin-fixed and paraffin-embedded 
tissues were cut into 5 micron slices and mounted on slides by the Comparative Biosciences 
Histology Laboratory at the College of Veterinary Medicine at UIUC. Hematoxylin and eosin 
(H&E) stained adipocytes were scanned at 20x by Nanozoomer slide scanning system (Hamatsu, 
Hamamatsu City, Japan). The area and diameter of adipocytes was calculated using Adiposoft 
software plugin for Image J (NIH, Bethesda, MD). Following analysis in automated mode, each 
individual image was evaluated for improper gating. Adipocytes that touched the field border were 
removed. Average adipocyte diameter and area were calculated from 100 randomly selected 
adipocytes from three fields within each individual tissue sample.  
Statistics 
Data was evaluated for errors and normality and transformed when appropriate. Food logs were 
analyzed using Nutrition Data System for Research software (99). Participants were stratified into 
two groups based on whether they had Obres or Obsen. Participants were categorized as Obres if they 
had a baseline HOMA-IR>2.5, a documented diagnosis of prediabetes or diabetes or a current 
prescription of anti-diabetic medications per electronic medical chart review. If these 
characteristics were not present, participants were categorized as Obsen. The majority of the cohort 
met criteria for Obres (66%) while 34% of the cohort met criteria for Obsen. To minimize potential 
confounding factors, patients with Obres were matched by age, sex, and BMI to Obsen patients. The 
distribution of males to females was not significantly different between Obsen and Obres groups (p= 
0.67). However, since our cohort was 78% female, only women were included in this analysis. 
Participants taking Thiazolidinediones (TZDs) or other antidiabetics which alter PPAR-γ and thus, 
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may alter adipocyte size were excluded. After matching and exclusions, there were ten participants 
available for comparison in each group (Appendix 5). Ideal body weight was estimated based on 
a reference BMI of 25 kg/m2 and used to calculate excess body weight loss (EBWL) during the 
pre- and postoperative period. General linear models and t-tests were used to test the difference 
between Obsen and Obres groups. Correlations between other variables such as anthropometric data, 
FetA and HOMA-IR were evaluated using Spearman Correlation Coefficients. Fisher’s exact test 
was used for categorical analysis. 
5.3 Results   
Insulin-sensitive and insulin-resistant obesity 
At baseline, the Obsen and Obres groups (n=10 women each) were not significantly different in age, 
BMI, percent body fat, triglycerides or LDL-cholesterol (Table 5.1). Individuals with Obsen had 
greater (p=0.005) baseline HDL than Obres (51.3mg/dl vs. 35.5mg/dl). As expected, those with 
Obres had elevated HOMA-IR at baseline. Although HOMA-IR declined during the preoperative 
diet, the Obres group still had higher (p=0.008) average HOMA-IR on the day of surgery than the 
Obsen group. Following SG, there was no longer a significant difference in HOMA-IR between 
groups (Fig. 5.1). The time lapse between appointments was not significantly different between 
the groups (22±12 days between T0 and T1 and 44±11 days between T1 and T2). Reported intake 
at baseline was not different between groups except for intake of polyunsaturated fatty acids which 
was higher (p=0.03) in individuals with Obsen than their counterparts (9.1±0.9 vs. 6.8±0.6% of 
total calorie intake) (Table 5.2). Dietary intake during the preoperative diet and postoperative 
period did not differ between groups except protein intake during the preoperative diet (Appendix 
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6). Individuals with Obres reported consuming greater (p=0.03) percent protein on T1 (24.9±1.1 
vs. 21.3±1.1%). 
The most significant predictor of excess body weight loss and BMI change was baseline BMI and 
time. Unadjusted preoperative, postoperative and total weight loss over the course of this study 
was not significantly different between Obsen and Obres groups. However, when adjusted for 
baseline BMI and time, the Obres group had more (p= 0.012) EBWL than the Obsen group (-29% 
vs. -26%) (Table 5.3). The Obres group also had greater (p=0.006) decline in BMI (-6.0 vs. -5.2 
kg/m2).  
Adipocyte size 
Adipocyte size was not significantly altered by SNPs in PPAR-γ (rs1801282 and rs2279525) FTO 
(rs8057044) or AHSG (rs4917 and rs2518136). Carriers of the G-allele at rs4986790, a SNP in 
TLR4, had larger (p=0.025) adipocyte diameter than non-carriers regardless of baseline BMI 
(62.8±2.4 vs. 73.7±3.6 µm). This finding was replicated in the entire cohort (Appendix 7). 
Adjusting for this association, we found that the Obres group had larger (p=0.0099) adipocytes than 
the Obsen group (70.6±2.2 vs. 60.6±2.5 µm) (Fig. 5.2). The genotype distribution of rs4986790 was 
not significantly different between Obsen and Obres groups (Fisher’s p=0.37). Adipocyte diameter 
was positively associated with baseline HOMA-IR (r=0.50, p=0.05) (Fig. 5.3). 
Circulating fetuin-A in insulin-sensitive and insulin-resistant obesity  
FetA was strongly correlated with age (r= -0.59, p=0.006). Age-adjusted FetA tended (p=0.09) to 
be higher in Obsen than Obres at T0 (667±42 vs. 562±42 µg/mL). On the morning of surgery, FetA 
did not differ (p=0.10) between groups (Obsen: 577±24 vs. Obres: 515±25 µg/mL). However, the 
Obsen had a greater (p=0.01) reduction in age-adjusted FetA when compared to Obres (-89±40vs. -
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47±40 µg/mL). Change in FetA following SG, was not significantly different between groups 
(Obsen: -117±32 vs. Obres: -151±32 µg/mL p=0.19). FetA was higher (p=0.004) in the Obsen group 
than the Obres group at T2 (461±20 vs. 364±20 µg/mL) (Fig. 5.4).  
Fetuin-A and adipocyte size 
Adipocyte size was strongly correlated (p=0.007) with preoperative change in FetA (r=0.64). 
Achievement of greater FetA reduction during the preoperative diet was associated with smaller 
adipocytes on the day of surgery (Fig. 5.5, A). Postoperatively, there was an opposite trend 
(p=0.07) between FetA and adipocyte size (r= -0.47). Individuals with larger adipocytes on the 
day of surgery had greater postoperative change in FetA (Fig. 5.5, B). Change in preoperative FetA 
was not associated with reported changes in caloric or macronutrient intake or preoperative 
changes in PBF or BMI. Postoperative change in FetA was not associated with reported 
postoperative dietary changes or changes in PBF. However, postoperative FetA change was 
positively associated (p=0.012) with change in BMI (r=0.55). 
5.4 Discussion  
Insulin-sensitive and insulin-resistant obesity 
In agreement with Leslie et al., we found that diet-induced preoperative weight loss did not differ 
based on insulin sensitivity status (169). However, postoperative weight loss was significantly 
greater in those with Obres. Changes in HOMA-IR were not consistent between the groups. 
Individuals with Obres had greater decreases in HOMA-IR during the preoperative diet. This 
reduction was maintained during the postoperative period. Interestingly, HOMA-IR in the Obsen 
group remained stable over the course of the study, showing little improvement over time. Karelis 
et al. demonstrated a similar phenomenon when they found greater improvements in insulin 
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sensitivity in Obres following diet-induced weight loss (171). These findings suggest that 
individuals with Obres experience superior short-term outcomes in terms of weight loss and 
improvements in insulin sensitivity. 
A limitation to this finding is that hyperinsulinemic-euglycemic clamp data was not available for 
this cohort. Although HOMA-IR is commonly used in the study of insulin resistance, there are no 
established cut-points for insulin resistance. Also, HOMA-IR correlates more so to hepatic glucose 
production rather than glucose utilization and insulin sensitivity as measured by a 
hyperinsulinemic-euglycemic clamp (154). Thus, future studies should consider additional 
markers for insulin sensitivity beyond HOMA-IR. 
In comparing the dietary intake of adults with Obres and Obsen, we replicated previous reports of 
altered fat consumption (30). Specifically, we found that those with Obsen consumed less saturated 
fat (p=0.106) and more (p=0.031) percent of calories from polyunsaturated fat at baseline. Previous 
studies of calorie restriction and overfeeding have demonstrated simultaneous reductions and 
elevations of FetA, respectively (113,115). However, in the I-OWLS cohort, change in FetA was 
not correlated with change in reported calorie or macronutrient intake. The lack of correlation 
between dietary change and change in FetA in our cohort was unexpected. Although a portion 
estimation tool and detailed instructions were provided to I-OWLS participants before collection 
of three-day food logs, it is possible that dietary reports may not have been accurate.  
Adipocyte Size 
Adipose tissue expands to accommodate excess fatty acids by either 1) hyperplasia, the increase 
in adipocyte number or 2) hypertrophy, the increase in adipocyte size. Hypertrophied adipose cells 
have been associated with insulin resistance and greater cytokine and lipid release (162,172). Like 
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previous reports, we found that HOMA-IR was positively associated with omental adipocyte size 
and that individuals with Obres had larger omental adipocytes (31,155). In contrast to previous 
studies, we were able to evaluate the influence of SNPs in genes such as PPAR-γ, TLR4, and FTO, 
which may predispose an individual to have larger or smaller adipocytes. We are the first to show 
a correlation between adipocyte size and the TLR4 polymorphism, rs4986790. However, carriers 
of the G-allele at rs4986790 have been shown to have greater liver, visceral and total body fat 
(173). By adjusting for rs4986790, a larger difference of average adipose diameter between the 
Obres and Obsen groups was reported. Although adipose tissue is difficult to obtain and adipocyte 
measurement is labor-intensive, this finding warrants replication in larger cohorts. Furthermore, 
the present study evaluated adipocyte size using H&E staining. Other technology, such as particle 
size analyzers, would allow for the measurement of 3D cell size rather than a singular plane.  
Circulating Fetuin-A in Insulin-Sensitive and Insulin-Resistant Obesity 
Individuals with Obsen had higher circulating FetA than those with Obres which conflicts with 
results from previous reports (31,119,174). One exception found that FetA was not different 
between groups (175). These reports measured circulating FetA in serum, whereas plasma was 
used in the current study. The same commercial kit was used for all but one (119) of the studies 
(BioVendor™). Importantly, the studies above evaluated FetA in different populations. Reinehr et 
al. evaluated adolescents (174), Yang et al. evaluated Asian bariatric patients (119) and Kloting et 
al. evaluated a convenience sample of adults with similar age and BMI to our cohort, however, the 
participants were undergoing elective surgeries, including cholecystectomy, exploratory 
laparotomy and SG (31). Our population strictly included SG participants. 
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FetA is recognized as a negative acute phase protein, however, the response of FetA to chronic 
inflammation is less clear. In dialysis patients, greater circulating C-reactive protein (CRP) is 
associated with lower FetA (92,176). Thus, our finding that Obres had lower FetA than Obsen, may 
be due to the chronic inflammation associated with insulin-resistance. Additionally, omega-3 
supplementation has been shown to increase FetA in dialysis patients and decrease FetA in patients 
with T2DM (177,178). The Obsen group consumed greater PUFAs than the Obres group which may 
suggest improvements in inflammatory status leading to higher circulating FetA. Although non-
alcoholic liver disease increases circulating FetA, information concerning liver status was not 
available in this cohort (83, 122).  
Fetuin-A and Adipocyte Size 
Greater preoperative reduction in FetA was associated with smaller adipocytes on the day of 
surgery while reported changes in dietary intake, body fat loss or BMI loss were not associated 
with adipocyte size. The mechanistic relationship between FetA and adipocyte size is not entirely 
clear. Two possible explanations include: 1) the relationship of FetA with PPAR-γ and 2) the 
complex interaction of FetA with inflammatory markers (Fig. 5.6-5.7).  
PPAR-γ is a nuclear receptor that plays an important role in adipocyte differentiation and lipid 
metabolism (179). PPAR-γ is primarily found in the adipose tissue. Upon forming a heterodimer 
with retinoid X receptor, PPAR-γ may be stimulated by ligands including but not limited to TZDs 
and fatty acids (180). Contrary to FetA which preferentially binds saturated fatty acids, PPAR-γ 
preferentially binds polyunsaturated fatty acids (180,181). Activated PPAR-γ increases 
transcription of proteins such as adiponectin, lipoprotein lipase and adipocyte binding protein and 
decreases cytokines such as TNFα and IL-6 (182–185). Thus, PPAR-γ activation is associated with 
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greater lipid uptake and adipogenesis (167,186). Accordingly, PPAR-γ knockout mice have 
smaller adipocytes and are more insulin-resistant following a high-fat diet (187). PPAR-γ activity 
is inhibited via Wnt signaling. For adipogenesis to occur, suppression of Wnt signaling is essential 
(188). Agarwal et al. recently demonstrated that FetA upregulates Wnt3A thus decreasing PPAR-
γ (167). Therefore, greater reductions in FetA may relieve suppression of PPAR-γ and allow for 
hyperplasia. However, if FetA remains elevated, Wnt-suppression of PPAR-γ may lead to 
adipocyte hypertrophy and unopposed proinflammatory cytokine release (185,189) 
Because omental adipocyte diameter was only measured at one time point during this study, it is 
also possible that change in adipocyte size influences circulating FetA. In fact, activation of PPAR-
γ via TZDs increases insulin sensitivity and reduces FetA expression in liver (190). Chronic use 
of TZDs leads to a greater risk for osteoporosis, a condition also associated with reduced FetA 
(191,192). It is possible that activation of PPAR-γ leads to a reduction of hepatic FetA output. 
Thus, the directionality of this relationship remains unclear and warrants further investigation.  
The relationship between FetA and adipocyte size may also be related to inflammatory status. 
When bound to saturated fat, FetA may stimulate the inflammatory cascade via TLR4 (98). FetA 
has been shown to promote macrophage migration into the adipose tissue in vitro (34). Adipose 
tissue macrophages contribute additional inflammatory cytokines to the environment (193). 
Researchers have shown that macrophage infiltration and inflammation decreases after bariatric 
surgery in mice (194,195). It is possible that these results are related to the postoperative reduction 
in circulating FetA. 
The present study is unable to determine whether the reduction in circulating FetA after bariatric 
procedures is due to a reduction in adipose- or liver-derived FetA. However, adipose expression 
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of FetA does appear to be related to adiposity status. Adipose from obese adults with T2DM had 
three times higher FetA expression than adipose tissue from normal weight humans without T2DM 
(97). Obese rats had increased FetA expression in visceral AT compared to lean rats (196). Thus, 
it is possible that weight loss led to reduced expression of FetA from the adipocyte. Another 
limitation was that the present study collected only omental fat at the time of surgery. Perez-Sotelo 
et al. demonstrated that visceral and subcutaneous FetA production responded differently to 
fasting. (196). Specifically, omental fat expression of FetA was reduced by fasting while 
subcutaneous fat expression of FetA was not. It is possible that subcutaneous tissue responds 
differently to obesity, insulin resistance and changes in FetA.  
5.5 Conclusion 
Previous studies found that FetA was elevated in adults with Obres supporting the potential role of 
FetA as a biomarker for distinguishing Obres from Obsen. Contrary to these studies, we found that 
participants with Obsen had higher FetA which remained higher than their Obres peers following 
preoperative diet and SG. The rationale for this conflicting finding is not clear. It is possible that 
chronically elevated inflammatory status common in Obres may play a role in reducing FetA which 
is also a well-known negative acute phase protein. Regardless of insulin-sensitivity group, greater 
reduction in FetA during the preoperative diet was associated with smaller adipocyte size on the 
day of surgery. Therefore, decreasing circulating FetA may suggest a reduction in adipocyte size 
which correlates with improved insulin sensitivity. Because this study only measured adipose 
tissue at one time point, longitudinal studies of histology changes are needed to support our finding 
further.  
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Table 5.1. Baseline characteristics of individuals with insulin-sensitive and insulin-
resistant obesity 
Variable 
Insulin-Resistant 
Obesity  
(n=10) 
Insulin-Sensitive 
Obesity  
(n=10) 
p-value 
Age, years (range) 44.2 ± 2.1 (36-57) 44.5 ± 2.0 (37-55) 0.920 
BMI (kg/m2) 46.1 ± 1.7 (39-55) 45.9 ± 1.7 (40-54) 0.940 
Body Fat (%) 51.9 ± 0.6 (48-54) 52.0 ± 0.6 (48-55) 0.869 
TG (mg/dL)   151.4 ± 17.6  134.0 ± 19.4 0.637 
TC (mg/dL)   172.3 ± 11.2 207.6 ± 13.4 0.058 
HDL (mg/dL)   35.5 ± 3.3 51.3 ± 4.8 0.005 
LDL (mg/dL) 103.2 ± 9.5 124.9 ± 12.3 0.179 
Glucose (mg/dL)   112.2 ± 5.18 95.5 ± 2.2 0.003 
HOMA-IR     4.0 ± 0.5   1.4 ± 0.1 <0.0001 
Values are presented as means ± SE. p-values greater than 0.05 are considered statistically significant. 
Abbreviations: BMI: Body Mass Index; TG: Triglycerides; TC: Total Cholesterol; LDL: Low Density Lipoprotein; 
HDL: High Density Lipoprotein; HOMA-IR: Homeostatic Model Assessment for Insulin Resistance. 
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Figure 5.1. HOMA-IR trajectory by insulin resistance status. HOMA-IR was transformed for 
analysis and back-transformed for graphical representation. Values are adjusted for time and presented as 
LSmeans ± SE. **p=<0.0001, *p=0.008, p-value for T2:0.22 
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Table 5.2. Reported baseline dietary intake of individuals with insulin-sensitive and 
insulin-resistant obesity 
Variable 
Insulin-Resistant 
Obesity  
(n=8) 
Insulin-Sensitive 
Obesity 
(n=9) 
p-value 
Total Kcal  1512 ± 215 1908 ± 246 0.302 
Kcal/kg     12 ± 1.9    15 ± 2.1 0.244 
Carbohydrate (% of total kcal)  41.7 ± 2.7 42.6 ± 2.0  0.777 
Protein (% of total kcal)  19.9 ± 0.9 19.3 ± 2.2  0.798 
Fat (% of total kcal)  37.6 ± 2.2 37.0 ± 2.3 0.844 
Saturated Fat (% of total kcal)  14.0 ± 1.3 10.8 ± 1.2 0.106 
PUFA (% of total kcal)    6.8 ± 0.6    9.1 ± 0.9 0.031 
MUFA (% of total kcal)  13.0 ± 1.1 13.3 ± 0.8 0.820 
Values are presented as means ± SE. p-values greater than 0.05 are considered statistically significant.  
Abbreviations: Kcal: kilocalorie; Kg: kilogram; PUFA: polyunsaturated fatty acids; MUFA: monounsaturated 
fatty acids. 
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Table 5.3. Weight loss in insulin-sensitive and insulin-resistant obesity 
Variable 
Insulin-Resistant 
Obesity  
(n=10) 
Insulin-Sensitive 
Obesity 
(n=10) 
p-value 
Preoperative EBWL -10.3 ± 1.3   -9.5 ± 1.3 0.675 
Postoperative EBWL -18.4 ± 1.3 -17.1 ± 1.3 0.0006 
Total EBWL -29.0 ± 1.5  -26.4 ± 1.5 0.012 
Preoperative PBF Δ    0.4 ± 0.4    0.4 ± 0.4 0.114 
Postoperative PBF Δ  -1.9 ± 0.4   -1.8 ± 0.4 0.904 
Total PBF Δ  -1.6 ± 0.4   -1.4 ± 0.4 0.768 
Preoperative BMI Δ  -2.3 ± 0.2  -2.0 ± 0.2 0.045 
Postoperative BMI Δ  -3.7 ± 0.3  -3.3 ± 0.3 0.025 
Total BMI Δ  -6.0 ± 0.3  -5.2 ± 0.3 0.006 
Data presented as mean ± SE. Values are adjusted by time and baseline BMI. Abbreviations: 
EBWL: excess body weight loss based on an ideal BMI of 25 kg/m2; PBF: percent body fat 
calculated by direct segmental multi-frequency bioelectrical impedance; BMI: body mass index. 
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Figure 5.2. Adipocyte diameter by insulin resistance status and toll-like receptor 4 (TLR4) 
(rs4986790) genotype. Group average is represented by black bar. When adjusted for TLR4 rs4986790 
genotype, those with insulin-resistant obesity had larger average adipocyte diameter (70.6 ± 2.2 µm) than 
those with insulin-sensitive obesity (60.6 ± 2.5 µm).  
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Figure 5.3. Association of adipocyte diameter and baseline HOMA-IR. 
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Figure 5.4. Fetuin-A trajectory by insulin resistance status. Data are adjusted for age and presented 
as LSmeans ± SE. p-value for T0: 0.09, p-value for T1: 0.10, p-value for T2: 0.004. 
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Figure 5.5. Association of adipocyte size on the day of surgery with preoperative and 
postoperative change in Fetuin-A.  Data includes a subset of the I-OWLS cohort which were age- 
and sex-matched for insulin sensitivity status. For complete cohort data see Appendix 8.
A. 
B. 
r=0.65 
p=0.007 
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Figure 5.6. Activation of PPAR-γ within the adipocyte. PPAR-γ is activated during the fed state and by Thiazolidinediones (TZD). Activated PPAR-
γ inhibits NF-Kβ and WNT3a activity and also stimulates transcription of genes related to lipid transport and metabolism. Thus, fatty acid uptake and lipogenesis 
in the cell are increased. Transcription of inflammatory cytokines is suppressed. Activation of PPAR-γ increases adipogenesis and reduces hepatic transcription of 
Fetuin-A. In the fed state, insulin signals glucose transport 4 (GLUT4) to translocate to the cell wall allowing glucose to enter the adipocyte. Figure not drawn to 
scale. Abbreviations: LPL: lipoprotein lipase; FABP: fatty acid binding protein, TNFα: tumor necrosis factor-alpha; IL: interleukin. 
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Figure 5.7. Inhibition of PPAR-γ within the adipocyte. PPAR-γ is inhibited during fasting and in response to elevated NF-Kβ and WNT3a signaling. 
Thus, transcription of genes related to lipid transport and metabolism are reduced. Inhibition of PPAR-γ reduced adipogenesis and allows for greater hepatic release 
of Fetuin-A (FetA). FetA stimulates Wnt3a which further inhibits PPAR-γ. FetA inhibits insulin receptor tyrosine kinase which prevents glucose transporter 
(GLUT4) translocation and limits glucose uptake. FetA binds saturated fatty acids (SFA) and stimulates a proinflammatory cascade via toll-like receptor 4. 
Cytokine release and elevated FetA attract additional monocytes and macrophages into the cellular environment. Overall, this leads to reduced adipogenesis and 
greater lipolysis, gluconeogenesis and inflammation in adipose tissue. Figure not drawn to scale.  
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CHAPTER 6. CONCLUSIONS AND FUTURE DIRECTIONS 
 
Summary 
The overarching goal of this research was to understand whether FetA may be a novel marker of 
obesity and comorbidities. Specifically, we investigated the association between obesity, 
circulating FetA and AHSG polymorphisms and evaluated change in FetA following bariatric 
surgery. We found that AHSG genotype was associated with circulating FetA and triglycerides but 
not with BMI or waist circumference in a college-aged Mexican population. Genetic variation in 
AHSG (rs4917 and rs2518236) explained 8-10% of the variability in FetA. Next, we investigated 
the response of FetA to SG, an effective treatment for T2DM. Circulating FetA was significantly 
reduced following both the preoperative and postoperative period. Total change in FetA was 
associated with percent weight loss. Unexpectedly, we found that HOMA-IR at all time points was 
strongly associated with postoperative FetA rather than FetA at the corresponding time point. 
Contrary to previous studies which suggest a positive association, we found that higher HOMA-
IR was associated with lower postoperative FetA. One possible explanation is that individuals with 
the greatest HOMA-IR are more responsive to changes in FetA whereas those with lower HOMA-
IR do not have the same capacity for change.  
Considering the significant change in FetA during this period and the association with weight 
change and insulin resistance, we sought to determine whether individuals with Obres responded 
differently to bariatric surgery than those Obsen. We found that baseline BMI and PBF did not 
differ between groups, yet, the Obres group had significantly more excess body weight loss, lower 
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FetA and larger omental adipocytes. Preoperative reduction in FetA was associated with smaller 
adipocytes on the day of surgery. 
When our results are considered along with the current body of evidence, it appears that FetA is a 
marker at the interface of insulin resistance, obesity and inflammation. Biomarkers can be used 
clinically to 1) screen and identify at-risk patients, 2) diagnose patients or 3) indicate disease 
progression or influence treatment intervention (197). At this time, FetA does not appear to fit 
strictly in any one of these categories. However, FetA decreases in response to weight loss and 
insulin sensitivity improvements, and greater FetA change is correlated with smaller adipocyte 
size, a known contributor to adipose insulin sensitivity (162). These data support the potential role 
of FetA as a biomarker of insulin sensitivity improvement following lifestyle and bariatric 
intervention. FetA may also be a promising addition to cumulative risk scores including other 
known biomarkers of obesity and insulin resistance. As with all research endeavors, the present 
research has revealed gaps in our understanding of not only FetA but also obesity and bariatric 
surgery.  
Future Directions 
Future directions for FetA research 
Future objectives in FetA should include establishing reference ranges for FetA and improving our 
understanding of FetA and inflammation. Because FetA is influenced by many disease states such 
as T2DM, non-alcoholic fatty liver disease and end-stage renal disease, it is challenging to set 
standard values and identify disease-specific cut points. An additional complication to our 
understanding of “normal” FetA is the complex interactions of FetA and inflammation. FetA is a 
negative acute phase protein that also promotes proinflammatory cytokine release from adipocytes, 
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acts as a chemokine and reduces expression of adiponectin, a known anti-inflammatory agent 
(94,97,98,167,198). Furthermore, the active form of FetA, phosphofetuin, has seldom been 
measured. One study demonstrated that phosphofetuin, but not FetA was significantly reduced by 
four days of exercise. Thus, it is possible that our results may have differed if we were able to 
measure phosphofetuin (199).  
While the results presented in Chapter 5 concerning the association of FetA change and adipocyte 
size are thought-provoking, the longitudinal correlation of FetA with adipose size has not been 
established. Although adipose is difficult to obtain, especially omental adipose, trials of at least 
two time points would better clarify whether adipocyte hypertrophy is the cause or consequence 
of FetA change. Chapter 4 concluded that FetA was significantly reduced following preoperative 
diet. This decline was not attributed to any specific macro- or micronutrient. Due to the possibility 
of dietary reporting errors, the use of controlled feeding trials and metabolomics may elucidate 
this mechanism and dietary correlates. We presented evidence that FetA is reduced six weeks 
following SG. Although FetA has been shown to remain lower than baseline for up to a year 
postoperatively, the trajectory of FetA after this point remains unknown (119).  
Future directions for bariatric surgery 
Bariatric surgery is a rapidly evolving practice (42). Further clinical studies are needed to evaluate 
long-term outcomes, efficacy in specific populations and novel procedures and devices. Recently 
approved weight loss devices such as the ReShape Dual Balloon System and the AspireAssist 
obesity device, offer additional, reversible options to patients with morbid obesity. However, 
studies of long-term safety and efficacy are needed. In general, the study of bariatric outcomes 
would benefit from studies which seek to evaluate health benefits beyond weight loss.  
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Research to date has not uncovered preoperative factors which predict successful weight loss. One 
topic of interest to all weight loss interventions is how chronic weight cycling influences an 
individual’s ability to lose and keep off excess weight. A recent animal study demonstrated that 
weight cycling may influence fat distribution (200). Thus, making this an important variable to 
study in the understanding of adipocyte function. 
To understand weight cycling history in the I-OWLS cohort, we collected follow-up surveys from 
a subset of participants one year postoperatively (n=22). On average, these patients reported trying 
12.4±5.0 different weight-loss strategies before surgery. The most common weight loss strategies 
attempted were counting calories, reducing intake of sweets and limiting portions (Appendix 10). 
Risky behaviors such as taking diet pills (59%), completing cleanses (27%), taking laxatives 
(23%), or smoking more cigarettes (9%) were also reported. I-OWLS participants reported 
purposely losing 10 pounds or more 9.8±8.9 times in their life. They also reported regaining as 
much as 10 pounds they had previously lost 10.3±8.6 times in their life. These data suggests that 
weight cycling, also known as yo-yo dieting, is common practice in bariatric populations. To date, 
it is not clear whether previous dieting attempts influence ability to lose weight following bariatric 
surgery.  
An additional area of uncertainty is the influence of genetics on post-bariatric outcomes. Genetics 
may influence outcomes by altering key proteins involved in the mechanisms of action for bariatric 
surgery. As suggested in the literature review, over 150 SNPs have been associated with human 
obesity (19). Many of these genetic variants were identified in cross-sectional analyses of large 
cohorts. Evidence for the influence of genes on weight loss trajectories remains sparse. Available 
studies focus primarily on change in BMI and fail to consider change in body composition, insulin 
sensitivity and other markers of metabolic health. If genetic variants are found to be useful 
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predictive variables, genetic analysis could be incorporated into preoperative care to improve 
procedure selection, maximize patient outcomes and avoid unnecessary risk in those who may 
have less success. Genetic markers that are found to be associated with bariatric outcomes may 
also reveal important insights into the mechanisms of action behind bariatric procedures. One 
example is the post-surgical reduction in the hunger hormone, ghrelin.  
Ghrelin is secreted by the stomach and thus, is decreased following SG (57). This may contribute 
to the reported reduction in hunger postoperatively (55). To determine the role of ghrelin 
polymorphisms in surgery-induced weight loss, we conducted a preliminary, exploratory analysis 
in the I-OWLS cohort described previously. Genomic DNA was extracted from white blood cells 
and total plasma ghrelin was measured using a commercially available kit (EMD Millipore, 
Billerica, MA). We found that T/T-homozygotes at the ghrelin polymorphism rs27647 lost 1.3±0.6 
BMI units more than C/T heterozygotes and 1.4±0.7 BMI units more than C/C-homozygotes 
postoperatively (p=0.04) (Appendix 11). Postoperative body fat loss was significantly higher in 
carriers of the rare rs696217 G/T genotype (p=0.05) (Unpublished data presented by Robinson et. 
al, ObesityWeek 2016). Although the sample size of the I-OWLS cohort was not adequately 
powered to detect genetic associations, the association of rs696217 with greater weight loss was 
recently replicated in a larger cohort of RYGB patients (201). 
Bariatric research is also moving toward a better understanding of efficacy in specific, unique 
populations. As more children are developing morbid obesity, studies concerning the safety and 
efficacy of bariatric procedures in children and adolescents are warranted (1). It is estimated that 
the number of bariatric procedure performed on adolescents tripled between 2000 and 2003 and 
has remained steady since this time (202). Specifically, 2.4 per 100,000 adolescents received 
bariatric surgery in 2009. Of which, 68% selected RYGB. Although large observational studies 
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such as Teen-Longitudinal Assessment of Bariatric Surgery (Teen-LABS) are in progress, long-
term follow-up remains a challenge especially in this transitional population (203). 
The present study found that six weeks following SG, individuals with obres had significant 
improvements in HOMA-IR. In fact, individuals with obres had similar HOMA-IR values as those 
with obsen at this time point. Large trials have concluded that 80% of patients who receive SG 
experience diabetes resolution (44,45). Bariatric procedures have even been suggested to be the 
“cure” for diabetes (204). Thus, the use of bariatric surgery in individuals with T2DM and a lower 
BMI (30-35 kg/m2) has been proposed. One study found that the use of RYGB in patients with 
class I obesity led to an 88% resolution of diabetes six years postoperatively (205). This 
demonstrates that bariatric surgery is an effective treatment for T2DM in adults with class I 
obesity.  
Current eligibility criteria (>35 kg/m2 with comorbidities or >40 kg/m2) may not be appropriate 
for all ethnic groups. At a BMI of 30 kg/m2, diabetes incidence is 11% of Caucasians, 25% of 
African Americans, 30% of Asians and 40% of South Asians (206). If BMI category cut points are 
adjusted for ethnic groups to match the diabetes incidence risk of Caucasians at a BMI of 30 kg/m2 
(11%), BMI cut points would be 26 kg/m2 for African Americans, 25 kg/m2 for Asians and 24 
kg/m2 for South Asians (206). Therefore, although these individuals are at a greater risk for 
diabetes, they may not have the option of bariatric surgery based on current eligibility criteria from 
the American Society for Metabolic and Bariatric Surgery (207,208).  
Criticism of the BMI is common in obesity research. Many question whether diagnostic criteria 
for obesity should rest solely on BMI (209). As we and others have demonstrated, metabolic health 
can vary even at a similar BMI values (31,154,159). BMI fails to account for body composition 
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(lean body mass to fat ratio), fat distribution and ethnic-specific differences (209,210). 
Additionally, it is now widely recognized that adipose tissue possesses the ability to influence 
other organs in the body through the release of cytokines and adipokines and through mechanical 
stress (211). It is not entirely clear why some individuals can evade these processes while other 
experience their deleterious effects. However, strong evidence connects adipocyte hypertrophy 
with suboptimal adipocyte function (162,163). Future research should seek to uncover non-
invasive biomarkers which predict omental adipocyte size in an attempt to better understand 
adipocyte health. Although much remains to be discovered, the present research contributes 
meaningful data towards a better understanding of FetA in insulin sensitivity, response to bariatric 
surgery and adipocyte health.  
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APPENDIX 1. DISTRIBUTION OF FETUIN-A IN NORMAL WEIGHT 
POPULATION 
 
 
 
Fetuin-A distribution in normal weight population. The Non-Invasive Measures of Insulin 
Sensitivity (NIMIS) cohort included 72 non-diabetic adults (37 males) recruited from the University of 
Illinois at Urbana-Champaign. Age ranged from 18-35 years old. Fetuin-A was measured using a 
commercially-available enzyme-linked immunosorbent assays from BioVendor™ (Asheville, NC). 
Average (± SD) Fetuin-A was 287 ± 57 μg/mL. 
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APPENDIX 2. BODY MASS INDEX, PERCENT BODY FAT, FASTING 
BLOOD GLUCOSE AND FETUIN-A IN NORMAL WEIGHT AND OBESE 
POPULATIONS 
 
  
Association of body mass index, percent body fat and fasting blood glucose with Fetuin-A in 
normal weight and obese population. The Non-Invasive Measures of Insulin Sensitivity (NIMIS) 
cohort included 72 adults (37 males) recruited from the University of Illinois at Urbana-Champaign. Age 
ranged from 18-35 years old. The Inflammatory Outcomes of Weight Loss Surgery (I-OWLS) study 
included 39 sleeve gastrectomy (SG) candidates prior to preoperative diet and prior to SG. In both studies, 
Fetuin-A was measured using a commercially-available enzyme-linked immunosorbent assay from 
BioVendor™ (Asheville, NC). Body fat percentage was measured using bioelectrical impedance analysis 
(InBody230, Biospace, Cerritos, CA).  
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APPENDIX 3. CORRELATION TABLE OF PREOPERATIVE AND POSTOPERATIVE CHANGES IN 
FETUIN-A AND BODY COMPOSITION 
  
   Preoperative Change     Postoperative Change 
   BMI 
Percent 
BW 
Percent 
EBWL 
PBF FetA Time     BMI 
Percent 
BW 
Percent 
EBWL 
PBF FetA Time 
P
re
o
p
er
a
ti
v
e 
C
h
a
n
g
e
 
HOMA-
IR 
0.11 0.17 0.19 0.17 -0.08 0.19  
P
re
o
p
er
a
ti
v
e 
C
h
a
n
g
e
 
HOMA-
IR 
0.02 0.01 0.10 -0.10 -0.18 -0.20 
0.576 0.378 0.308 0.381 0.661 0.316  0.897 0.944 0.608 0.599 0.343 0.273 
BMI  
  0.92 0.73 0.00 0.38 0.28  BMI 
  0.84 0.58 0.21 0.48 -0.70 
  <.0001 <.0001 0.996 0.039 0.128    <.0001 0.001 0.257 0.008 <.0001 
BW 
    0.94 0.15 0.39 0.26  BW 
    0.91 0.15 0.43 -0.54 
    <.0001 0.429 0.032 0.161      <.0001 0.422 0.018 0.002 
EBW 
      0.30 0.37 0.21  EBW 
      0.18 0.27 -0.43 
      0.097 0.045 0.263        0.321 0.141 0.016 
PBF 
        0.04 0.27  PBF 
        0.05 -0.21 
        0.813 0.141          0.804 0.269 
FetA 
          -0.03  FetA 
          -0.15      
0.867            0.418 
   
      
  
 
      
   BMI 
Percent 
BW 
Percent 
EBWL 
PBF FetA Time    BMI 
Percent 
BW 
Percent 
EBWL 
PBF FetA Time 
P
re
o
p
er
a
ti
v
e 
C
h
a
n
g
e
 
HOMA-
IR 
0.13 0.18 0.32 0.23 -0.57 -0.40  
P
o
st
o
p
er
a
ti
v
e 
C
h
a
n
g
e
 
HOMA-
IR 
0.63 0.23 0.23 0.30 0.15 -0.50 
0.756 0.668 0.491 0.586 0.141 0.326  0.097 0.576 0.618 0.465 0.719 0.204 
BMI  
  0.86 0.16 -0.86 0.17 -0.02  BMI 
  0.78 0.46 0.21 0.15 -0.68 
  0.003 0.713 0.003 0.668 0.969    0.013 0.257 0.583 0.691 0.046 
BW 
    0.78 -0.70 0.02 -0.36  BW 
    0.91 0.36 0.39 -0.80 
    0.022 0.035 0.969 0.345      0.002 0.338 0.295 0.010 
EBW 
      0.06 -0.37 -0.66  EBW 
      0.95 0.23 -0.83 
      0.882 0.361 0.074        0.0004 0.588 0.010 
PBF 
        -0.42 -0.30  PBF 
    
-0.25 -0.70 
        0.259 0.431          0.515 0.035 
FetA 
          0.16  FetA 
          -0.27 
          0.682            0.485 
 
Each cell contains the Pearson correlation coefficient (r) followed by the p-value for the correlation. P<0.05 were considered statistically 
significant. Abbreviations: HOMA-IR: homeostatic model assessment for insulin resistance; BMI: body mass index; BW: body weight; EBWL: 
excess body weight loss; PBF: percent body fat; FetA: Fetuin-A. Time is a measure of days between visits. 
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APPENDIX 4. FETUIN-A CHANGE BY ALPHA2-HEREMANS-SCHMID 
GLYCOPROTEIN (AHSG) POLYMORPHISM  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Change in Fetuin-A (FetA) by AHSG (rs4917) genotype. In chapter three, AHSG genotype was 
shown to be associated with circulating FetA. Thus, I-OWLS participants were stratified by rs4917 
genotype for this exploratory analysis of the association between AHSG genotype and age-adjusted FetA 
change (Δ). P-values<0.1 are included in the figure although only p-values<0.05 are considered statistically 
significant. Genotype distribution was: CC (n=16), CT (n=22) and TT (n=2) thus, replication in larger 
cohorts is needed. 
p=0.07 
p=0.08 
p=0.05 
p=0.09 
p=0.05 
p=0.09 
p=0.05 
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APPENDIX 5. PARTICIPANT CATEGORIZATION AS INSULIN-
SENSITIVE OR INSULIN-RESISTANT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Categorization of I-OWLS participants as insulin-sensitive or insulin-resistant. Participants 
were considered to have Obres if they had a baseline HOMA-IR>2.5, a documented diagnosis of prediabetes 
or diabetes or current prescription of anti-diabetic medications. If these characteristics were not present, 
participants were considered to have Obsen. Patients with Obres were matched by age, sex, and BMI to Obsen 
patients. Participants taking Thiazolidinediones (TZDs) which alter PPAR-γ and thus, may alter adipocyte 
size were excluded.  
1 participant opted out of surgery 
42 visits on the  
day of surgery  
(T1) 
45 consented 
44 initial visits 
(T0) prior to 
preoperative diet 
2 participants switched to another 
bariatric procedure prior to surgery 
1 participant opted out of surgery 
1 lost to follow-up 
 40 follow-up 
visits six-weeks  
after surgery (T2) 
1 did not have plasma available for 
analysis of FetA or HOMA-IR at T2 
38 available for 
categorization 
5 had no tissue available for histology  
3 used Thiazolidinediones 
5 males 
6 age (n=5) or BMI extremes (n=1) 
10 women with insulin- 
sensitive obesity 
10 age- and BMI- 
matched women with 
insulin-resistant obesity 
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APPENDIX 6. COMPARISON OF PRE- AND POSTOPERATIVE 
DIETARY INTAKE BETWEEN INSULIN-SENSITIVE AND INSULIN-
RESISTANT OBESITY 
 
Preoperative diet comparison by insulin-sensitive and insulin-resistant obesity status 
Variable 
Insulin-Resistant 
Obesity  
(n=10) 
Insulin-Sensitive 
Obesity 
(n=10) 
p-value 
Total Kcal 914 ± 43          1059 ± 93 0.166 
Kcal/kg   7.6 ± 0.4   8.7 ± 0.8 0.241 
Carbohydrate (% of total kcal) 60.0 ± 1.7 63.3 ± 2.1 0.238 
Protein (% of total kcal) 24.9 ± 1.1 21.3 ± 1.1 0.033 
Fat (% of total kcal) 15.1 ± 2.1 15.4 ± 1.7 0.907 
Saturated Fat (% of total kcal)   3.3 ± 0.4   4.0 ± 0.4 0.178 
PUFA (% of total kcal)   3.6 ± 0.9   3.3 ± 1.0 0.810 
MUFA (% of total kcal)   6.0 ± 1.2   5.6 ± 0.8 0.772 
Three-day food logs were collected on the day of surgery. Values are presented as means ± SE. p-values greater 
than 0.05 are considered statistically significant.  Abbreviations: Kcal: kilocalorie; Kg: kilogram; PUFA: 
polyunsaturated fatty acids; MUFA: monounsaturated fatty acids. 
 
 
 
Postoperative diet comparison by insulin-sensitive and insulin-resistant obesity status 
Variable 
Insulin-Resistant 
Obesity  
(n=10) 
Insulin-Sensitive 
Obesity 
(n=9) 
p-value 
Total Kcal 640.6 ± 89.7   867.1 ± 134.6 0.166 
Kcal/kg   5.9 ± 1.0   7.7 ± 1.2 0.281 
Carbohydrate (% of total kcal) 34.5 ± 5.1 32.2 ± 3.8 0.726 
Protein (% of total kcal) 32.5 ± 2.9 30.6 ± 2.4 0.623 
Fat (% of total kcal) 32.4 ± 3.3 37.1 ± 2.8 0.292 
Saturated Fat (% of total kcal) 10.3 ± 1.9 11.1 ± 1.9 0.779 
PUFA (% of total kcal)   4.9 ± 0.9   7.6 ± 1.2 0.076 
MUFA (% of total kcal) 12.2 ± 1.1 13.7 ± 1.4 0.373 
Three-day food logs were collected six weeks following surgery. Values are presented as means ± SE. p-values 
greater than 0.05 are considered statistically significant.  Abbreviations: Kcal: kilocalorie; Kg: kilogram; PUFA: 
polyunsaturated fatty acids; MUFA: monounsaturated fatty acids. 
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APPENDIX 7. ADIPOCYTE DIAMETER BY INSULIN RESISTANCE 
STATUS AND TOLL-LIKE RECEPTOR 4 GENOTYPE  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adipocyte diameter by insulin resistance status and toll-like receptor 4 (rs4986790) genotype 
in the I-OWLS cohort. Participants with incomplete data or current prescription for Thiazolidinediones 
were excluded from this analysis. Thus, hematoxylin and eosin stained tissue samples were available from 
24 participants in the I-OWLS cohort. Data represents all available samples stratified by insulin status but 
unmatched for other demographic variables such as sex, age or BMI. Group average is represented by black 
bar. 
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APPENDIX 8. ASSOCIATION OF OMENTAL ADIPOCYTE DIAMETER 
AND CHANGE IN FETUIN-A.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Association of adipocyte size on the day of surgery with preoperative, postoperative and 
total change in Fetuin-A.  Data includes all participants of the I-OWLS cohort which had omental 
adipose tissue available for H&E staining (n=29).   
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APPENDIX 9. SURVEY MEASURES COLLECTED FROM THE I-OWLS 
LONGITUDINAL COHORT 
  
Measure T0 T1 T2 T3 
Demographics  
Ethnicity, sex, age 
X    
Self-reported weight X X X X 
Current diagnosis of common obesity-associated diseases X X X X 
Family history of common obesity-associated diseases X    
Perceived age and cause of excess weight gain X    
Children’s Body Image Scale and Adult Body Size Guide (212,213) X    
Health beliefs and perceived barriers Modified from (214) X   X 
International Physical Activity Questionnaire (215) X X X X 
Patient Health Questionnaire (PHQ-9) (216) X X X X 
Three-day food log and nutritional supplement use X X X X 
Additional demographics 
Marital status, education level 
   X 
Dieting strategies Modified from (6)    X 
Weight cycling patterns (217)    X 
Bariatric support group attendance    X 
Outcome satisfaction survey     X 
Sleep Quality Assessment (218)    X 
Taste and Smell Questionnaire Modified from (219,220)    X 
Three-Factor Eating Questionnaire (221)    X 
An “X” indicates that this survey or measure was collected from participants at the given time point: T0: baseline, 
T1: the morning of surgery, T2: six-weeks postoperatively and T3: one year postoperatively. 
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APPENDIX 10. WEIGHT-LOSS STRATEGIES USED BY I-OWLS 
COHORT PRIOR TO BARIATRIC SURGERY 
 
  
Weight-Loss Strategy N Percentage 
Counting calories 19 86% 
Reducing intake of sweets 19 86% 
Limiting portions 18 82% 
Consuming low-calorie foods 15 68% 
Reducing intake of carbohydrates 15 68% 
Avoiding eating after a certain time of night 15 68% 
Eating packaged diet meals 15 68% 
Keeping a food log 14 64% 
Decreasing fat intake 14 64% 
Reducing snacking 14 64% 
Skipping meals 14 64% 
Taking diet pills 13 59% 
Increasing physical activity or exercise 12 55% 
Increasing fruit and vegetable consumption 11 50% 
Using an appetite suppressant 11 50% 
Consuming a liquid diet 7 32% 
Eating slower 6 27% 
Fasting for a day 6 27% 
Completing a "cleanse" or detox 6 27% 
Taking caffeine pills 6 27% 
Taking laxatives 5 23% 
Reducing intake of meat 4 18% 
Reducing alcohol intake 4 18% 
Fasting for more than a day 3 14% 
Using diuretics 3 14% 
Increasing cigarette smoking 2 9% 
Purging 1 5% 
  
 
Retrospective report of weight-loss strategies used by I-OWLS cohort prior to sleeve 
gastrectomy. One year following sleeve gastrectomy, participants of the I-OWLS cohort were asked to 
complete an online survey concerning preoperative dieting strategies and weight cycling. On average, 
survey respondents (n=22), attempted 12.4(±5.0) different weight-loss strategies prior to surgery (range: 4-
21 strategies). Respondents reported purposefully losing 10 lbs or more 9.8(±8.9) times in their life and 
regaining as much as 10 lbs they had previously lost 10.3(±8.6) times in their life.  
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APPENDIX 11. WEIGHT LOSS FOLLOWING SLEEVE GASTRECTOMY 
IS INFLUENCED BY GHRELIN GENE POLYMORPHISMS 
  
   
 
Exploratory analysis of circulating ghrelin, weight loss and ghrelin gene polymorphisms in 
the I-OWLS cohort (n=39). Fasting total ghrelin was measured in plasma using enzyme-linked immunosorbent 
assays. Participants were genotyped for two ghrelin gene polymorphisms (rs27647 and rs696217). Values are 
presented as means ± SE. A. Ghrelin was significantly reduced following sleeve gastrectomy but not preoperative 
diet. B. When stratified by ghrelin genotype (rs27647), circulating ghrelin was not significantly different at each time 
point although variability was reduced at T2. C. T/T-homozygotes at rs27647 lost 1.3 ± 0.6 BMI units more than C/T 
heterozygotes and 1.4 ± 0.7 BMI units more than C/C-homozygotes postoperatively (p=0.04). N=31. Values were 
adjusted by sex, age, time interval and baseline BMI. D. Postoperative body fat loss was significantly higher in carriers 
of the rare rs696217 G/T genotype (p=0.05). Values were adjusted by sex, age, time interval and baseline percent 
body fat. This data was presented at the ObesityWeek conference in 2016 (New Orleans, LA) and received first place 
in the Early Career Education Theater and was the rated top abstract in the Clinical Management of Obesity Section. 
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APPENDIX 12. PROTOCOL FOR THE MEASUREMENT OF PLASMA 
FETUIN-A USING COMMERCIALLY-AVAILABLE ENZYME-LINKED 
IMMUNOSORBENT ASSAYS 
  
Department of Food Science and Human Nutrition Protocol No. SOP-MT-102 
Standard Operating Procedure 
Title: Measuring Plasma Fetuin-A using ELISA  
Written by: Katie N. Robinson 
Version No. 
Issue Date 
002 
4/6/2015 
  
 
1. OBJECTIVE 
1.1. This procedure outlines the measurement of circulating Fetuin-A using the BioVendor 
ELISA kit. The kit measures Fetuin-A in serum and plasma (collected in EDTA, citrate or 
heparin tubes). Samples should be assayed immediately after collection or should be stored 
at -80°C. 
 
NOTE: Blood is considered a potentially infectious material therefore caution shall be 
excised when handling samples 
 
2. SCOPE 
2.1. This SOP is applicable to all research collaborators. 
 
3. RESPONSIBILITY 
3.1. It is the responsibility of the principal investigator (PI) in conjunction with the research 
collaborators to ensure that all blood samples are handled in a proper manner.  
3.2. It is the responsibility of the PI in conjunction with research collaborators to ensure that all 
research participants are adequately instructed on the procedures to be followed for 
analyzing blood samples.  
3.3. All reagents should be stored at 2-8°C prior to use. Opened reagents are stable for 3 months. 
Check expiration date prior to use. 
 
4. PREPARATION of MATERIALS 
 
4.1. Label 1.5mL tubes for the dilutions (two tubes for each sample, labeled A and B) and for 
the standard curve (one tube for each: 40 ng/ml, 20 ng/ml, 10 ng/ml, 5 ng/ml and 2 ng/ml). 
 
4.2. Thaw reagents for one hour at room temp. Thaw samples on ice. 
 
4.3. Dilute Dilution Buffer Concentrate (10x) ten-fold in distilled water to prepare a 1x 
working solution. Check the refrigerator for previously-made buffer.  
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4.3.1. In a 250ml glass container, with a lid, you will add 20 ml of Dilution Buffer 
Concentrate (10x) + 180 ml of distilled water for use in all 96-wells.  
 
4.3.2. Add half of the distilled water, then the dilution buffer. Rinse the dilution buffer 
container with remaining distilled water. Invert to mix. Avoid making bubbles. 
4.3.3. Stability and storage: The diluted Dilution Buffer is stable 1 month when stored at 
2-8°C.  
 
4.4. Prepare samples. Mix thoroughly thawed samples just prior to the assay and avoid 
repeated freeze/thaw cycles, which may cause erroneous results. Make note of samples 
with hemolysis or lipemia. 
4.4.1. First, add 990 µl of Dilution Buffer into each 1.5mL tube. 
4.4.2. Dilute samples 10 000x with Dilution Buffer just prior to the assay in two steps as 
follows:  
4.4.3. Dilution A (100x): Add 10 µl of sample into the “A” set of tubes (pre-filled with 
990 µl of Dilution Buffer) and mix well (not to foam). Vortex is recommended. 
4.4.4. Dilution B (100x): Add 10 µl of Dilution A into the “B” set of tubes (pre-filled with 
990 µl of Dilution Buffer) to prepare final dilution (10 000x) and mix well (not to 
foam). Vortex is recommended. 
4.4.5. Stability and storage: Do not store the diluted samples. 
 
4.5. Refer to the Certificate of Analysis for current volume of Dilution Buffer needed for 
reconstitution of standard. 
 
4.6. Reconstitute the lyophilized Master Standard with Dilution Buffer just prior to the assay 
with 1.3ml of dilution buffer to obtain a concentration of 100ng/ml. Invert to mix. Let it 
dissolve at least 15 minutes with occasional gentle shaking (not to foam). 
 
4.7. Quality Controls HIGH and LOW. Refer to the Certificate of Analysis for current 
volume of Dilution Buffer needed for reconstitution and for current Quality Control 
concentration. 
4.7.1. Reconstitute each Quality Control (HIGH and LOW) with Dilution Buffer just prior 
to the assay.  
4.7.2. QC HIGH - Add 1.6ml of dilution buffer to the vial.  
4.7.3. QC LOW – Add 1.6ml of dilution buffer to the vial. 
4.7.4. Let dissolve at least 15 minutes with occasional gentle shaking (not to foam). Do 
not store the reconstituted Quality Controls.  
 
4.8. Wash Solution Conc. (10x) Dilute Wash Solution Concentrate (10x) 10-fold in distilled 
water to prepare a 1x working solution.  
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4.8.1. Add 100 ml of Wash Solution Concentrate (10x) + 900 ml of distilled water for use 
in all 96-wells. Add half of the water to a 1000mL glass container. Then add the 
wash solution. Rinse wash solution container with remaining water.  
4.8.2. Stability and storage: The diluted Wash Solution is stable 1 month when stored at 
2-8°C.  
 
4.9. Prepare the set of standards using the Master Standard (which should now be at 
100ng/ml). Follow the table below: 
 
5. PROCEDURE  
5.1. Pipet 100 µl of diluted Standards, Quality Controls, Dilution Buffer (=Blank) and samples, 
preferably in duplicates, into the appropriate wells. See example from BioVendor.  
 
5.2. Incubate the plate at room temperature (25°C) for 1 hour, shaking at 300 rpm on an orbital 
microplate shaker. 
 
5.3. Wash the wells 3-times with Wash Solution (300 µl per well).  
5.3.1. Aspirate wells by flicking the contents into the sink.  
5.3.2. Pipet 300 µl Wash Solution into each well (use multichannel or electric pipette). 
Aspirate wells. Repeat this process twice.  
Volume of Standard  Dilution Buffer  Concentration  
Stock  -  100 ng/ml  
200 µl of stock  300 µl  40 ng/ml  
250 µl of 40 ng/ml  250 µl  20 ng/ml  
250 µl of 20 ng/ml  250 µl  10 ng/ml  
250 µl of 10 ng/ml  250 µl  5 ng/ml  
200 µl of 5 ng/ml  300 µl  2 ng/ml  
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5.3.3. After final wash, invert and tap the plate strongly against paper towel. Make certain 
that Wash Solution has been removed entirely. 
 
5.4. Add 100 µl of Conjugate Solution into each well. 
 
5.5. Incubate the plate at room temperature (25°C) for 1 hour, shaking at 300 rpm on an orbital 
microplate shaker. 
 
5.6. Wash the wells 3-times with Wash Solution (300 µl per well). After final wash, invert and 
tap the plate strongly against paper towel. 
 
5.7. Add 100 µl of Substrate Solution into each well. Avoid exposing the microtiter plate to 
direct sunlight. Covering the plate with the silver container that the plate came in or 
aluminum foil is recommended. Label with the current time and the stop time. 
 
5.8. Incubate the plate for 10 minutes at room temperature. The incubation time may be 
extended [up to 20 minutes] if the reaction temperature is below than 20°C. Do not shake 
the plate during the incubation. 
 
5.9. In the meantime, turn on the laptop and VICTORx5 plate reader. 
 
5.10. Stop the color development by adding 100 µl of Stop Solution. 
 
5.11. Determine the absorbance of each well using a microplate reader set to 450 nm, preferably 
with the reference wavelength set to 630 nm (acceptable range: 550 - 650 nm). Subtract 
readings at 630 nm (550 - 650 nm) from the readings at 450 nm. The absorbance should be 
read within 5 minutes following step 5.10. 
_____________________________________________________________________________________
Additional laboratory standard operating procedures which were developed or amended by Katie Robinson include:  
1. General Laboratory Safety 
2. Laboratory Waste Management and Autoclave  
3. Proper Use of the Biological Safety Cabinet 
4. Saliva Collection from Adults 
5. Breath Collection from Children and Proper Storage  
6. Bioelectrical Impedance Analysis using InBody 230 
7. Agarose Gel Preparation 
8. RNA Extraction from Adipose Tissue and rtPCR 
9. Genotype Analysis using Fluidigm Software 
10. Calculating Adipocyte Diameter Using Adiposoft 
